var title_f6_57_7056="Contents: Interstitial lung disease";
var content_f6_57_7056=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?8/24/8590\">",
"       Pulmonary, Critical Care, and Sleep Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Interstitial lung disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Interstitial lung disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Connective tissue disorders and vasculitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/34/27177\">",
"           Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/45/26329\">",
"           Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/28/9674\">",
"           Clinical spectrum of antineutrophil cytoplasmic antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/40/30344\">",
"           Drug-induced lung disease in rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/56/21383\">",
"           Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/35/35382\">",
"           Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/40/16008\">",
"           General principles of the use of cyclophosphamide in rheumatic and renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/32/34314\">",
"           Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/32/16906\">",
"           Interstitial lung disease associated with Sj������gren's syndrome: Clinical manifestations, evaluation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/37/25174\">",
"           Interstitial lung disease associated with Sj������gren's syndrome: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/7/24697\">",
"           Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/7/8313\">",
"           Interstitial lung disease in dermatomyositis and polymyositis: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/31/17912\">",
"           Interstitial lung disease in rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/21/26969\">",
"           Overview of lung disease associated with rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/20/33097\">",
"           Pathogenesis of granulomatosis with polyangiitis (Wegener���������s) and related vasculitides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/19/7482\">",
"           Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/60/11210\">",
"           Pulmonary manifestations of systemic lupus erythematosus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/49/6935\">",
"           Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/14/21738\">",
"           Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/33/35353\">",
"           Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug-induced disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/4/29767\">",
"           Amiodarone pulmonary toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/31/12794\">",
"           Bleomycin-induced lung injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/34/37415\">",
"           Busulfan-induced pulmonary injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/26/41380\">",
"           Chlorambucil-induced pulmonary injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/30/21990\">",
"           Cyclophosphamide pulmonary toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/32/37384\">",
"           Differentiation (retinoic acid) syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/40/30344\">",
"           Drug-induced lung disease in rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/6/34918\">",
"           Gold-induced pulmonary disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/5/9306\">",
"           Methotrexate-induced lung injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/46/33513\">",
"           Mitomycin-C pulmonary toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/52/27462\">",
"           Nitrofurantoin-induced pulmonary injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/42/28327\">",
"           Nitrosourea-induced pulmonary injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/34/38439\">",
"           Overview of pulmonary disease in injection drug users",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/53/34649\">",
"           Pulmonary complications of cocaine abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/44/19143\">",
"           Pulmonary disease induced by cardiovascular drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/41/17050\">",
"           Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/49/29466\">",
"           Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/42/13993\">",
"           Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38344\">",
"           Taxane-induced pulmonary toxicity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/20/22856\">",
"           Approach to the adult with interstitial lung disease: Clinical evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/18/16681\">",
"           Approach to the adult with interstitial lung disease: Diagnostic testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/41/25239\">",
"           Basic principles and technique of bronchoalveolar lavage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/62/5096\">",
"           Evaluation of diffuse lung disease by conventional chest radiography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/23/4474\">",
"           Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/63/21497\">",
"           Interpretation of lung biopsy results in interstitial lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/24/23945\">",
"           Nonresolving pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/36/16968\">",
"           Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/26/424\">",
"           Role of lung biopsy in the diagnosis of interstitial lung disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemoptysis and pulmonary hemorrhage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/28/9674\">",
"           Clinical spectrum of antineutrophil cytoplasmic antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/24/14727\">",
"           Etiology and evaluation of hemoptysis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/32/34314\">",
"           Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4409\">",
"           Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/16/7432\">",
"           Treatment of anti-GBM antibody (Goodpasture's) disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypersensitivity pneumonitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/49/19222\">",
"           Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/12/1225\">",
"           Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/18/34087\">",
"           Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/34/7719\">",
"           Treatment and prognosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Idiopathic pulmonary fibrosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/23/4474\">",
"           Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/39/32378\">",
"           Pathogenesis of idiopathic pulmonary fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/60/34762\">",
"           Treatment of idiopathic pulmonary fibrosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Occupational lung disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/5/16472\">",
"           Asbestosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/45/22234\">",
"           Chronic beryllium disease (berylliosis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/61/28629\">",
"           Nylon flock worker's lung",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/23/33145\">",
"           Silicosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22792\">",
"           Acute interstitial pneumonia (Hamman-Rich syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/43/24247\">",
"           Bronchiolitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/28/44484\">",
"           Bronchocentric granulomatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/10/12458\">",
"           Clinical manifestations and diagnosis of bronchiectasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/62/8168\">",
"           Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/60/19402\">",
"           Cryptogenic organizing pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/20/18759\">",
"           Diagnosis and treatment of pulmonary alveolar proteinosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43769\">",
"           Diffuse panbronchiolitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/58/24490\">",
"           Diseases of the chest wall",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/44/37575\">",
"           Emphysema-like disease in HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/39/31353\">",
"           Foreign body granulomatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/32/25098\">",
"           General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/14/1255\">",
"           Idiopathic acute eosinophilic pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/51/12089\">",
"           Idiopathic pulmonary hemosiderosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/26/43430\">",
"           Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/25/409\">",
"           Lymphoid interstitial pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/47/27386\">",
"           Major side effects of systemic glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/25/42393\">",
"           Nonspecific interstitial pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/37/9817\">",
"           Primary ciliary dyskinesia (immotile-cilia syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/48/35592\">",
"           Pulmonary Langerhans cell histiocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/10/40106\">",
"           Pulmonary complications after allogeneic hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/25/14745\">",
"           Pulmonary complications after autologous hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29034\">",
"           Pulmonary complications of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/7/21623\">",
"           Pulmonary involvement in AIDS-related Kaposi sarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/1/5142\">",
"           Pulmonary involvement in tuberous sclerosis complex",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/30/4586\">",
"           Pulmonary lymphangioleiomyomatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/20/41287\">",
"           Pulmonary lymphomatoid granulomatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9750\">",
"           Pulmonary manifestations of HIV-associated lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/33/24090\">",
"           Radiation-induced lung injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34633\">",
"           Respiratory bronchiolitis-associated interstitial lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/61/23512\">",
"           The diffuse alveolar hemorrhage syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/11/38073\">",
"           Treatment of bronchiectasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/6/20581\">",
"           Treatment of chronic eosinophilic pneumonia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sarcoidosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/19/17722\">",
"           Cardiac sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/25/21914\">",
"           Clinical manifestations and diagnosis of sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/14/17638\">",
"           Gastrointestinal sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/8/20616\">",
"           Neurologic sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/14/6376\">",
"           Pathogenesis of sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/31/40438\">",
"           Renal disease in sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/12/11463\">",
"           Sarcoid arthropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/11/38074\">",
"           Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/43/11961\">",
"           Treatment of pulmonary sarcoidosis with glucocorticoids",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-166DC909B6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_57_7056=[""].join("\n");
var outline_f6_57_7056=null;
var title_f6_57_7057="Patient information: Pernicious anemia (The Basics)";
var content_f6_57_7057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pernicious anemia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pernicious-anemia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14571492\">",
"      <span class=\"h1\">",
"       What is pernicious anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pernicious anemia is a condition that happens when a person has too few red blood cells. Red blood cells are the cells in your blood that carry oxygen. If you have too few red blood cells, your body does not get all the oxygen it needs.",
"     </p>",
"     <p>",
"      To make red blood cells, your body needs vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      . Many foods contain vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      , including eggs, meat, poultry, and fish. Pernicious anemia happens when your body can&rsquo;t absorb vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      from the foods you eat. This happens because your stomach does not make a substance that your body needs to absorb B",
"      <sub>",
"       12",
"      </sub>",
"      . This substance is called &ldquo;intrinsic factor.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14571507\">",
"      <span class=\"h1\">",
"       What are the symptoms of pernicious anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with mild pernicious anemia might not have any symptoms. But if they have pernicious anemia for a long time, they can get symptoms that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tingling or burning feelings on the skin",
"       </li>",
"       <li>",
"        A tongue that is red, shiny, and sore",
"       </li>",
"       <li>",
"        Numbness",
"       </li>",
"       <li>",
"        Feeling tired and weak",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Trouble using their legs due to weakness or uncontrolled movements (called &ldquo;spasms&rdquo;)",
"       </li>",
"       <li>",
"        Trouble with balance while standing, especially at night",
"       </li>",
"       <li>",
"        Leaking urine or losing control of their bladder (called &ldquo;incontinence&rdquo;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with pernicious anemia might also have changes in how they feel and act, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Problems with memory and thinking (a condition called &ldquo;dementia&rdquo;)",
"       </li>",
"       <li>",
"        Mood problems, such as being cranky or grouchy",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14571522\">",
"      <span class=\"h1\">",
"       Is there a test for pernicious anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors use many different blood and urine tests to check for pernicious anemia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14571537\">",
"      <span class=\"h1\">",
"       How is pernicious anemia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pernicious anemia is treated with large doses of vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      . Most of the time, you will get an injection (shot) of vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      every day for 1 week. A nurse can show you (or a relative or friend) how to give the shots. Then you will need 1 shot per week for 4 weeks, followed by monthly shots of vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      for the rest of your life.",
"     </p>",
"     <p>",
"      In some cases, vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      can be taken in different forms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A pill that you swallow",
"       </li>",
"       <li>",
"        A tablet that you dissolve under your tongue",
"       </li>",
"       <li>",
"        A spray that you breathe in through your nose",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These treatments must be taken every single day for the rest of your life.",
"     </p>",
"     <p>",
"      No matter what form of treatment you use, it is very important to keep taking vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      . If you stop, you will get pernicious anemia again in about 3 years.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/57/7057?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83066 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-1D88657B2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7057=[""].join("\n");
var outline_f6_57_7057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14571492\">",
"      What is pernicious anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14571507\">",
"      What are the symptoms of pernicious anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14571522\">",
"      Is there a test for pernicious anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14571537\">",
"      How is pernicious anemia treated?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_57_7058="Pulmonary hypertension Lateral";
var content_f6_57_7058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary hypertension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph in lateral view showing decreased retrosternal space (arrow) due to right ventricular enlargement in pulmonary hypertension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sven Paulin, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lateral chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7058=[""].join("\n");
var outline_f6_57_7058=null;
var title_f6_57_7059="NASH Light";
var content_f6_57_7059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Nonalcoholic steatohepatitis on biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic changes in nonalcoholic steatohepatitis (NASH). Left panel: The hepatocyte in the center contains a large vacuole of fat and deeply staining eosinophilic strands of cytoplasmic hyalin. Numerous neutrophils and phagocytic cells containing golden brown pigmented material (bile components and cellular debris) are present in the sinusoids. Right panel: NASH with cirrhosis. Trichrome stain shows regenerating nodules with fat surrounded by fibrous tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7059=[""].join("\n");
var outline_f6_57_7059=null;
var title_f6_57_7060="Port wine stain pyogenic granuloma";
var content_f6_57_7060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma occurring in a port wine stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 5-year-old boy with a small port wine stain on the side of his right cheek extending onto the ear developed a 4 mm pyogenic granuloma within the capillary malformation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7060=[""].join("\n");
var outline_f6_57_7060=null;
var title_f6_57_7061="Acute tinea pedis KOH";
var content_f6_57_7061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute tinea pedis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Segmented, branched dermatophyte hyphae are visible on this KOH preparation from a patient with acute tinea pedis infection. KOH preparations of skin scrapings from all dermatophyte infections show similar hyphal structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7061=[""].join("\n");
var outline_f6_57_7061=null;
var title_f6_57_7062="Esomeprazole and naproxen: Patient drug information";
var content_f6_57_7062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Esomeprazole and naproxen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34072?source=see_link\">",
"     see \"Esomeprazole and naproxen: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10241634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vimovo&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12817167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vimovo&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10255462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10255647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691523",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat NSAID-associated gastric ulcers in patients with a history of ulcers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10255463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769819",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to naproxen, esomeprazole, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10255465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for soft, brittle bones called osteoporosis (alcohol use, cigarette smoking, other family members with brittle bones, taking drugs to treat seizures, taking steroids).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10255764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hip, spine, or wrist fractures may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10255467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10255649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695826",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10255464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10255765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10255468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15572 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7062=[""].join("\n");
var outline_f6_57_7062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241634\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817167\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10255462\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10255647\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10255463\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10255465\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10255764\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10255467\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10255649\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10255464\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10255765\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10255468\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34072?source=related_link\">",
"      Esomeprazole and naproxen: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_57_7063="Vitiligo - elbow";
var content_f6_57_7063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74712%7EDERM%2F63623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74712%7EDERM%2F63623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An irregularly shaped hypopigmented patch is present on the elbow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple depigmented macules and patches are present on the hands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7063=[""].join("\n");
var outline_f6_57_7063=null;
var title_f6_57_7064="Anemia chron dis marrow iron";
var content_f6_57_7064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Anemia of chronic disease - bone marrow iron stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Section of a bone marrow aspirate taken from a patient with the anemia of chronic disease. The slide has been stained for iron (Prussian blue reaction) and counterstained with safranin to show nuclear detail. Note the increased iron staining within the voluminous cytoplasm of macrophages (thick black arrows), while there is no staining for iron within the cytoplasm of red blood cell precursors (thin black arrows). This pattern (abundant iron in macrophages and reduced to absent iron in red cell precursors) is quite typical for the anemia of chronic disease, and contrasts with iron deficiency, in which iron is absent from both macrophages and red cell precursors, while normal subjects demonstrate iron in macrophages and red cell precursors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Slide provided by Stanley L. Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7064=[""].join("\n");
var outline_f6_57_7064=null;
var title_f6_57_7065="Classification and causes of jaundice or asymptomatic hyperbilirubinemia";
var content_f6_57_7065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/57/7065/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/57/7065/contributors\">",
"     Namita Roy-Chowdhury, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/57/7065/contributors\">",
"     Jayanta Roy-Chowdhury, MD, MRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/57/7065/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/57/7065/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/57/7065/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/57/7065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/57/7065/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/57/7065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal serum bilirubin concentration in children and adults is less than 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (17",
"    <span class=\"nowrap\">",
"     micromol/liter),",
"    </span>",
"    less than 5 percent of which is present in conjugated form. The measurement is usually made using diazo reagents and spectrophotometry. Conjugated bilirubin reacts rapidly (\"directly\") with the reagents. The measurement of unconjugated bilirubin requires the addition of an accelerator compound and is often referred to as the indirect bilirubin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36294?source=see_link\">",
"     \"Clinical aspects of serum bilirubin determination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Jaundice is often used interchangeably with hyperbilirubinemia. However, a careful clinical examination cannot detect jaundice until the serum bilirubin is greater than 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (34",
"    <span class=\"nowrap\">",
"     micromol/liter),",
"    </span>",
"    twice the normal upper limit. The yellow discoloration is best seen in the periphery of the ocular conjunctivae and in the oral mucous membranes (under the tongue, hard palate). Icterus may be the first or only sign of liver disease; thus its evaluation is of critical importance.",
"   </p>",
"   <p>",
"    For clinical purposes, the predominant type of bile pigments in the plasma can be used to classify hyperbilirubinemia into two major categories (",
"    <a class=\"graphic graphic_table graphicRef55607 \" href=\"UTD.htm?27/55/28541\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef50896 graphicRef62683 \" href=\"UTD.htm?23/30/24032\">",
"     algorithm 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma elevation of predominantly unconjugated bilirubin due to the overproduction of bilirubin, impaired bilirubin uptake by the liver, or abnormalities of bilirubin conjugation",
"     </li>",
"     <li>",
"      Plasma elevation of both unconjugated and conjugated bilirubin due to hepatocellular diseases, impaired canalicular excretion, and biliary obstruction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some situations, both overproduction and reduced disposition contribute to the accumulation of bilirubin in plasma.",
"   </p>",
"   <p>",
"    The frequency with which the different causes of jaundice occur varies markedly depending upon multiple factors such as age, geography, and socioeconomic class [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/1\">",
"     1",
"    </a>",
"    ]. The causes of hyperbilirubinemia presenting in the neonatal period are quite different from those presenting later in life, and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the causes of jaundice. A schematic depiction of the hepatobiliary excretion pathway with disorders causing jaundice and their main site of interference with bilirubin metabolism and excretion is presented in the figure (",
"    <a class=\"graphic graphic_figure graphicRef71005 \" href=\"UTD.htm?36/16/37127\">",
"     figure 1",
"    </a>",
"    ). The diagnostic approach to the patient with jaundice is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISORDERS ASSOCIATED WITH UNCONJUGATED HYPERBILIRUBINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three basic pathophysiologic mechanisms, overproduction of bilirubin, reduced bilirubin uptake, and impaired bilirubin conjugation, are mainly responsible for unconjugated hyperbilirubinemia. The physiologic jaundice of the neonate represents a classic example which combines all of these mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overproduction of bilirubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilirubin overproduction may result from excessive breakdown of heme derived from hemoglobin (",
"    <a class=\"graphic graphic_figure graphicRef65197 \" href=\"UTD.htm?12/7/12415\">",
"     figure 2",
"    </a>",
"    ). Extravascular or intravascular hemolysis, extravasation of blood in tissues, or dyserythropoiesis are causes of enhanced heme catabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Extravascular hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reticuloendothelial cells of the spleen, bone marrow, and liver are responsible for the increased extravascular destruction of erythrocytes which occurs in most hemolytic disorders. These phagocytic mononuclear cells are rich in heme oxygenase and biliverdin reductase activities and rapidly degrade heme to bilirubin (",
"    <a class=\"graphic graphic_figure graphicRef65197 \" href=\"UTD.htm?12/7/12415\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Extravasation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When blood is extravasated into tissues, erythrocytes are phagocytosed by tissue macrophages, which degrade heme to biliverdin and subsequently bilirubin, resulting in the sequential green and yellow discoloration of the skin overlying a hematoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Intravascular hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With intravascular hemolysis, bilirubin is predominantly formed in the liver and the kidneys. Hemoglobin released in the circulation is bound to haptoglobin; this complex is internalized and degraded by hepatocytes. However, circulating haptoglobin may be depleted with massive hemolysis. In these cases, unbound hemoglobin is converted to methemoglobin, from which heme is transferred to hemopexin or to albumin forming methemalbumin. Heme-hemopexin and methemalbumin are internalized by hepatocytes, where heme is degraded to bilirubin.",
"   </p>",
"   <p>",
"    A significant fraction of free methemoglobin is filtered by renal glomeruli after dissociation of the tetrameric globin to two dimers. Only the free (unbound) dimer is small enough to be filtered across the glomeruli. The heme moiety of filtered methemoglobin is largely degraded by tubular epithelial cells to bilirubin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Dyserythropoiesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyserythropoiesis is a term used in a variety of diseases including megaloblastic and sideroblastic anemias, severe iron deficiency anemia, erythropoietic porphyria, erythroleukemia, lead poisoning, and a rare disorder of unknown pathogenesis termed primary shunt hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In these disorders, the incorporation of hemoglobin into erythrocytes is defective, leading to the degradation of a large fraction of unincorporated hemoglobin heme.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Serum bilirubin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a stress situation, hemolysis, and therefore unconjugated bilirubin production, can increase up to 10-fold. The canalicular excretion of bilirubin is the rate limiting step in bilirubin elimination since hepatic conjugating capacity normally exceeds maximum bilirubin production. These relationships account for two findings at a steady state of maximum bilirubin production in patients with normal hepatic function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum bilirubin concentration will not exceed 4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (68",
"      <span class=\"nowrap\">",
"       micromol/liter)",
"      </span>",
"      in patients with normal liver function [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/4\">",
"       4",
"      </a>",
"      ]; however, hemolysis can lead to severe hyperbilirubinemia in patients who have even mild hepatic disease.",
"     </li>",
"     <li>",
"      The proportion of conjugated bilirubin in plasma (approximately 3 to 5 percent of the total) remains normal [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are two reasons why the bilirubin concentration increases during hemolysis in the presence of normal bilirubin glucuronidation. First, bilirubin is produced mainly outside the liver; as a result, it must enter the blood stream during transit to the liver. Second, a small amount of bilirubin taken up by the hepatocyte is transferred to plasma by diffusion or via ATP-consuming mechanisms. Because conjugated bilirubin is very efficiently cleared, the proportion of conjugated bilirubin in the plasma (around 5 percent) does not increase until canalicular excretion capacity is exceeded. At that point, a disproportionate amount of conjugated bilirubin accumulates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bilirubin overproduction with coexisting liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most liver diseases affect canalicular excretion, resulting in the accumulation of both conjugated and unconjugated bilirubin in hepatocytes. In cholestatic states, the canalicular ATP-dependent organic anion pump, MRP2, is down-regulated. This may lead to upregulation of other forms of MRP, such as MRP3, in the contiguous membranes of the hepatocyte, resulting in active transport of unconjugated and conjugated bilirubin into the plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Thus, plasma bilirubin accumulating in conditions resulting from a combination of bilirubin overload and liver disease is always a mixture of unconjugated and conjugated bilirubin. In cases where there is an inherited deficiency of conjugation (eg, Gilbert syndrome), hemolysis causes almost pure unconjugated hyperbilirubinemia. The rate-limiting step in these patients is bilirubin glucuronidation, rather than canalicular excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Urobilinogen excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;As bilirubin excretion in bile increases in states of bilirubin overproduction, more urobilinogen appears in the stool and urine. However, the amount of urobilinogen in stool and urine is not proportional to bilirubin excretion since conversion of bilirubin to urobilinogen is not quantitative [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gallstones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronically increased biliary bilirubin excretion can lead to brown or black pigment stones consisting of precipitated monoconjugated and unconjugated bile pigments. Black pigment stones generally form in the gallbladder and may contain polymerized bile pigments. Brown stones form in the bile ducts, often in the presence of infection. They consist of calcium bilirubinate, mucin glycoproteins, and various other salts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Impaired hepatic bilirubin uptake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired delivery of bilirubin to the liver and disorders of internalization of bilirubin by the hepatocyte result in reduced hepatic bilirubin uptake (",
"    <a class=\"graphic graphic_figure graphicRef52393 \" href=\"UTD.htm?30/51/31536\">",
"     figure 3",
"    </a>",
"    ). Congestive heart failure or portosystemic shunts (spontaneously occurring collaterals in cirrhosis or surgical shunts) reduce hepatic blood flow and the delivery of bilirubin to hepatocytes, resulting in predominantly unconjugated hyperbilirubinemia. In some patients with cirrhosis, the direct contact of plasma with the hepatocytes may be compromised due to capillarization of the sinusoidal endothelial cells (loss of fenestrae), resulting in a further reduction in bilirubin uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other causes of abnormal bilirubin uptake include Gilbert's syndrome, in which uptake of bilirubin at the sinusoidal surface of hepatocytes is impaired (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    ), and the administration of several drugs (eg, rifamycin antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    , flavaspadic acid, and bunamiodyl, a cholecystographic agent). The drug-induced defect usually resolves within 48 hours after discontinuation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Impaired bilirubin conjugation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced bilirubin conjugation as a result of a decreased or absent UDP-glucuronosyltransferase activity is found both in several acquired conditions and inherited diseases, such as Crigler-Najjar syndrome, type I and II and Gilbert's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6201?source=see_link\">",
"     \"Crigler-Najjar syndrome\"",
"    </a>",
"    .) Bilirubin conjugating activity is also very low in the neonatal liver.",
"   </p>",
"   <p>",
"    UGT activity toward bilirubin is modulated by various hormones. Hyperthyroidism and ethinyl estradiol, but not other oral contraceptives, inhibit bilirubin glucuronidation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/11\">",
"     11",
"    </a>",
"    ]. In comparison, the combination of progestational and estrogenic steroids results in increased enzyme activity. Bilirubin glucuronidation can also be inhibited by certain antibiotics (eg, novobiocin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    at serum concentrations exceeding therapeutic levels) and by chronic persistent hepatitis, advanced cirrhosis, and Wilson's disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DISORDERS ASSOCIATED WITH CONJUGATED HYPERBILIRUBINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of acquired disorders with conjugated hyperbilirubinemia can be categorized according to their histopathology and pathophysiology: biliary obstruction (extrahepatic cholestasis); intrahepatic cholestasis; and hepatocellular injury. The differential diagnosis of extrahepatic and intrahepatic hyperbilirubinemia is summarized in the tables (",
"    <a class=\"graphic graphic_table graphicRef73409 \" href=\"UTD.htm?19/11/19644\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71068 \" href=\"UTD.htm?38/58/39852\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Biliary obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In biliary obstruction, both conjugated and unconjugated bilirubin accumulate in serum. Bilirubin may be transported back to the plasma via a MRP group of ATP-consuming pumps [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. The serum concentrations of conjugated bilirubin and alkaline phosphatase can be used as markers for hepatobiliary obstruction. The diagnosis can usually be established with the help of noninvasive and invasive imaging techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obstruction of biliary flow causes retention of conjugated bilirubin within the hepatocytes, where reversal of glucuronidation may take place. The unconjugated bilirubin formed by this process may diffuse or be transported back into the plasma.",
"   </p>",
"   <p>",
"    The differential diagnosis of conjugated hyperbilirubinemia due to biliary obstruction is age dependent. In adults, it includes cholelithiasis, intrinsic and extrinsic tumors, primary sclerosing cholangitis (PSC), parasitic infections, lymphoma, AIDS cholangiopathy, acute and chronic pancreatitis, and strictures after invasive procedures. In children, choledochal cysts and cholelithiasis are most common. Extrinsic compression from tumors or other anomalies are seen in all pediatric age groups as well as in adults. In neonates, important obstructive processes include biliary atresia and choledochal cysts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Mirizzi syndrome, a distended gallbladder caused by an impacted cystic duct stone may lead to compression of the extrahepatic bile ducts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44565?source=see_link\">",
"       \"Mirizzi syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The intrahepatic and extrahepatic portions of the bile ducts can be affected in both PSC and cholangiocarcinoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Different parasitic infections can be the cause of biliary obstruction. Adult Ascaris lumbricoides can migrate from the intestine up the bile ducts, thereby obstructing the extrahepatic bile ducts. Eggs of certain liver flukes (eg, Clonorchis sinensis, Fasciola hepatica) can obstruct the smaller bile ducts, resulting in intrahepatic cholestasis.",
"     </li>",
"     <li>",
"      AIDS cholangiopathy can be caused by Cryptosporidium sp, cytomegalovirus, or HIV itself [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/13\">",
"       13",
"      </a>",
"      ]; imaging studies show similar findings to PSC [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=see_link\">",
"       \"AIDS cholangiopathy\"",
"      </a>",
"      .) Only biopsies and bile cultures are able to give a definitive diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Establishing the cause of jaundice in patients with AIDS is particularly complex because of its broad differential diagnosis. It includes viral hepatitis (hepatitis viruses, herpes simplex virus, Epstein-Barr virus), Mycobacterium tuberculosis and atypical mycobacteria (especially Mycobacterium avium intracellulare), fungal infections (Cryptococcus neoformans, Histoplasma capsulatum, Candida albicans, Coccidioides immitis), parasites (Pneumocystis carinii), tumor infiltration (lymphoma, Kaposi sarcoma), and drug-induced liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intrahepatic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of intrahepatic disorders can lead to jaundice and an elevated serum alkaline phosphatase (in relation to serum aminotransferases). This presentation mimics that of biliary obstruction but the bile ducts are patent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Viral hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral hepatitis can present as a predominantly cholestatic syndrome with marked pruritus. Unless the patient has risk factors for viral hepatitis, it is difficult to distinguish this clinically from other causes of cholestasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Alcoholic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholestasis with fever and leukocytosis is often the distinctive sign of alcoholic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/15\">",
"     15",
"    </a>",
"    ]. The diagnosis should be strongly considered in the jaundiced patient with ethanol dependency, especially if the ratio of serum AST to ALT exceeds 2.0 with the values being below 500 int.",
"    <span class=\"nowrap\">",
"     unit/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Nonalcoholic steatohepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;NASH has features similar to alcoholic hepatitis both in terms of histology and signs of cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/16\">",
"     16",
"    </a>",
"    ]. A variety of conditions such as diabetes mellitus, morbid obesity, certain stomach and small bowel operations, and drugs can cause this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Primary biliary cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary biliary cirrhosis typically presents with a cholestatic picture although evidence of hepatocellular injury also exists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Drugs and toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced cholestasis can occur in a dose-related fashion (eg, alkylated steroids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/36/3652?source=see_link\">",
"     methyltestosterone",
"    </a>",
"    and ethinyl estradiol) or as an idiosyncratic or allergic reaction in a minority of subjects (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    , halothane). Drugs and toxins causing hepatocellular injury may eventually present as a predominantly cholestatic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/17\">",
"     17",
"    </a>",
"    ]. Therefore, it is imperative in every patient with cholestasis to scrupulously elucidate the current and past medication history including prescribed and over-the-counter drugs.",
"   </p>",
"   <p>",
"    Certain plants used in \"natural\" medicines (eg, Jamaican bush tea) contain pyrrolizidine alkaloids which may cause veno-occlusive disease of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=see_link\">",
"     \"Hepatotoxicity due to herbal medications and dietary supplements\"",
"    </a>",
"    .) The outbreak of jaundice that occurred in 84 individuals after accidental methylene dianiline ingestion in England in 1965 has been termed Epping jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arsenic, which was used for the treatment of syphilis during the early years of the twentieth century, also can cause cholestasis. It has recently gained increased attention because of its contamination of ground water in various parts of the world including West Bengal, India [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/21\">",
"     21",
"    </a>",
"    ], the southern United States, and Taiwan. In addition to the well-known skin lesions, arsenic-contaminated drinking water has been associated with hepatic fibrosis and portal hypertension, usually without the formation of cirrhotic nodules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Sepsis and low perfusion states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial sepsis is very often accompanied by cholestasis. Multiple factors including hypotension, drugs, and bacterial endotoxins are responsible for the jaundice in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. On the other hand, hyperbilirubinemia can promote bacterial sepsis by increasing intestinal wall permeability and altering mucosal immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/25\">",
"     25",
"    </a>",
"    ]. Signs of cholestasis can also be found in other low perfusion states of the liver (heart failure, hypotension) and hypoxemia that is not profound enough to produce hepatic necrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic syndromes associated with malignancy can induce a reversible form of cholestasis (Stauffer syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/26\">",
"     26",
"    </a>",
"    ]. It has most commonly been described in association with renal cell carcinoma, although it has also been reported in patients with malignant lymphoproliferative diseases, gynecologic malignancies, and prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Liver infiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltrative processes of the liver (eg, amyloidosis, lymphoma, sarcoidosis, tuberculosis) can precipitate intrahepatic cholestasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Inherited diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated levels of conjugated bilirubin may occur in inherited diseases such as Dubin-Johnson syndrome, Rotor syndrome, progressive familial intrahepatic cholestasis (PFIC), benign recurrent intrahepatic cholestasis (BRIC), and low phospholipid-associated cholelithiasis (LPAC). BRIC is seen in adolescents and adults, while LPAC presents mainly in young adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link\">",
"     \"Inherited disorders associated with conjugated hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disorders of fatty acid oxidation are characterized by episodes of metabolic decompensation, with hypoglycemia, liver dysfunction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiomyopathy, triggered by fasting or intercurrent illness. These disorders may present at any age, from birth through adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link&amp;anchor=H18#H18\">",
"     \"Causes of metabolic myopathies\", section on 'Defects of beta-oxidation enzymes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inherited diseases that cause conjugated hyperbilirubinemia that present during the neonatal period include Alagille syndrome, cystic fibrosis, and disorders of carbohydrate, lipid, or bile acid metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Total parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steatosis, lipidosis, and cholestasis are frequently encountered in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN). This complication usually requires at least two to three weeks of therapy for the development of cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/29\">",
"     29",
"    </a>",
"    ]. The underlying illness, preexisting liver disease, hepatotoxic drugs, and the TPN itself all may contribute to the cholestasis.",
"   </p>",
"   <p>",
"    TPN promotes bacterial overgrowth in the small intestine which in turn favors conditions well-known to induce cholestasis such as translocation of intestinal endotoxins into the portal system [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/30\">",
"     30",
"    </a>",
"    ], bacterial sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/31\">",
"     31",
"    </a>",
"    ], and the formation of secondary bile acids (eg, lithocholic acid). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=see_link\">",
"     \"Management of the short bowel syndrome in adults\"",
"    </a>",
"    .) Other contributing factors to cholestasis include biliary sludge, which occurs in all patients after six weeks of TPN, and hepatotoxic factors such as tryptophan degradation products and aluminum contaminants.",
"   </p>",
"   <p>",
"    Infants are particularly prone to TPN cholestasis, particularly those born prematurely. Contributing factors and potential treatment approaches are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link&amp;anchor=H27#H27\">",
"     \"Causes of neonatal cholestasis\", section on 'Parenteral nutrition-associated liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Postoperative patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jaundice occurs regularly in postoperative patients and is usually multifactorial in origin. Serum unconjugated bilirubin levels may increase because of blood transfusions, hematoma resorption, and hemolysis after heart surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/32\">",
"     32",
"    </a>",
"    ]. Other contributing factors include sepsis, TPN, the administration of hepatotoxic drugs during surgery (such as halothane) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/33\">",
"     33",
"    </a>",
"    ], postoperative hypoxia, hypotension, or a newly acquired viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/34\">",
"     34",
"    </a>",
"    ]. Concomitant renal failure will exaggerate the hyperbilirubinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9718?source=see_link\">",
"     \"Approach to the patient with postoperative jaundice\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery also can exacerbate a preexisting hemolytic disease or unmask an underlying genetic disorder (eg, Gilbert's syndrome or glucose-6-phosphate dehydrogenase deficiency).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Following organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrahepatic cholestasis is common in transplant recipients (especially bone marrow and liver). These patients are generally very sick, often require TPN, and receive multiple potentially hepatotoxic drugs including immunosuppressive agents which increase the susceptibility to infection.",
"   </p>",
"   <p>",
"    In addition to the skin and intestinal epithelium, other target sites of graft-versus-host disease in bone marrow transplants include the small interlobular bile ducts. The resulting inflammation and destruction lead to cholestasis. Intensive pretransplantation radiation and chemotherapy predisposes to the development of veno-occlusive disease of the liver, with cholestasis and liver failure.",
"   </p>",
"   <p>",
"    Signs of cholestasis after orthotopic liver transplantation may reflect preservation injury of the donor organ, an operative complication (bile leak, stricture) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/35\">",
"     35",
"    </a>",
"    ], and chronic allograft rejection (\"vanishing bile duct syndrome\"). In addition, cholestasis is occasionally the sole indicator of acute transplant rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jaundice in patients with sickle cell disease can result from an interaction of several factors. The average serum bilirubin concentration in these patients is higher than normal because of the combination of chronic hemolysis and a mild hepatic dysfunction. Both unconjugated and conjugated bilirubin accumulate in the plasma. Viral hepatitis, particularly hepatitis C virus, also may contribute in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2842?source=see_link\">",
"     \"Hepatic manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatic crisis, which is usually associated with enlargement and tenderness of the liver, is thought to result from sequestration of sickled erythrocytes. In severe cases, acute attacks of intrahepatic cholestasis can occur, leading to very high levels of serum bilirubin and bile salts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/36\">",
"     36",
"    </a>",
"    ]. This condition must be differentiated from acute biliary obstruction. Bilirubin microliths, sludge, calcium bilirubinate stones, and black stones consisting of polymers of bilirubin are almost universal in patients with sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/37\">",
"     37",
"    </a>",
"    ]. However, biliary obstruction from these stones is not common.",
"   </p>",
"   <p>",
"    Finally, cirrhosis can be caused by chronic vascular lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/38\">",
"     38",
"    </a>",
"    ] or iron overload after multiple blood transfusions (secondary hemochromatosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Intrahepatic cholestasis of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus, usually occurring in the third trimester of pregnancy but sometimes earlier, typically heralds cholestasis which may evolve into frank jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/39\">",
"     39",
"    </a>",
"    ] and may be associated with an increased frequency of stillbirths and prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/40\">",
"     40",
"    </a>",
"    ]. All the pathologic changes disappear following delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=see_link\">",
"     \"Intrahepatic cholestasis of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intrahepatic cholestasis of pregnancy is thought to be inherited, although the mode of inheritance is not well-defined [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7065/abstract/41\">",
"     41",
"    </a>",
"    ]. A possible relationship to benign recurrent intrahepatic cholestasis has been postulated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .) It is of crucial importance to distinguish this entity from other, potentially lethal liver disorders in pregnancy such as acute fatty liver and the HELLP syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link\">",
"     \"Acute fatty liver of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     End-stage liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmarks of end-stage liver disease and cirrhosis, regardless of its etiology, include jaundice with an elevation of both conjugated and unconjugated bilirubin as well as portal hypertension and decreased hepatic synthetic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hepatocellular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;A partial overview of disorders causing hepatocellular jaundice is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef66083 \" href=\"UTD.htm?31/21/32093\">",
"     table 4",
"    </a>",
"    ). These conditions cannot always be separated clearly from the cholestatic syndromes because of the variability in presentation of these diseases. There are, however, characteristic differences between the two mechanisms of hepatic disease. Hepatocellular injury is typically characterized by the release of intracellular proteins and small molecules into the plasma. Thus, in contrast to cholestatic syndromes, the elevations in serum conjugated and unconjugated bilirubin and bile salts are accompanied by elevations in the serum concentrations of hepatocellular proteins, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and glutathione S-transferase (GST).",
"   </p>",
"   <p>",
"    With chronic hepatocellular injury, the biochemical profile changes over time as the liver injury progresses to cirrhosis and liver failure. The elevation of liver enzymes, a marker of active liver injury, becomes less prominent or even disappears. The primary manifestations at this time result from impaired hepatic protein synthesis (eg, hypoalbuminemia and a prolonged prothrombin time) and impaired excretory function, leading to jaundice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/17/34066?source=see_link\">",
"       \"Patient information: Jaundice in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/28/21953?source=see_link\">",
"       \"Patient information: Gilbert&rsquo;s syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An approach to patients with abnormal liver biochemical tests is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"       \"Approach to the patient with abnormal liver biochemical and function tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For clinical purposes, the predominant type of bile pigments in the plasma can be used to classify hyperbilirubinemia into two major categories, conjugated and unconjugated (",
"      <a class=\"graphic graphic_table graphicRef55607 \" href=\"UTD.htm?27/55/28541\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef50896 graphicRef62683 \" href=\"UTD.htm?23/30/24032\">",
"       algorithm 1A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Three basic pathophysiologic mechanisms, overproduction of bilirubin, reduced bilirubin uptake, and impaired bilirubin conjugation, are mainly responsible for unconjugated hyperbilirubinemia.",
"     </li>",
"     <li>",
"      A variety of acquired disorders with conjugated hyperbilirubinemia can be categorized according to their histopathology and pathophysiology: biliary obstruction (extrahepatic cholestasis); intrahepatic cholestasis; and hepatocellular injury. The differential diagnosis of extrahepatic and intrahepatic hyperbilirubinemia is summarized in the tables (",
"      <a class=\"graphic graphic_table graphicRef73409 \" href=\"UTD.htm?19/11/19644\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef71068 \" href=\"UTD.htm?38/58/39852\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/1\">",
"      Reisman Y, Gips CH, Lavelle SM, Wilson JH. Clinical presentation of (subclinical) jaundice--the Euricterus project in The Netherlands. United Dutch Hospitals and Euricterus Project Management Group. Hepatogastroenterology 1996; 43:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/2\">",
"      ROBINSON S, VANIER T, DESFORGES JF, SCHMID R. Jaundice in thalassemia minor: a consequence of \"ineffective erythropoiesis\". N Engl J Med 1962; 267:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/3\">",
"      Israels G, Zipursky A. Primary shunt hyperbilirubinemia due to an alternate path of bilirubin production. Am J Med 1959; 27:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/4\">",
"      Berk PD, Wolkoff AW, Berlin NI. Inborn errors of bilirubin metabolism. Med Clin North Am 1975; 59:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/5\">",
"      Snyder AL, Satterlee W, Robinson SH, Schmid R. Conjugated plasma bilirubin in jaundice caused by pigment overload. Nature 1967; 213:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/6\">",
"      Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001; 34:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/7\">",
"      Jansen PL, Roskams T. Why are patients with liver disease jaundiced? ATP-binding cassette transporter expression in human liver disease. J Hepatol 2001; 35:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/8\">",
"      WATSON CJ, WEIMER M. Composition of the urobilin group in urine bile, and feces and the significance of variations in health and disease. J Lab Clin Med 1959; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/9\">",
"      SCHAFFNER F, POPER H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963; 44:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/10\">",
"      Kenwright S, Levi AJ. Sites of competition in the selective hepatic uptake of rifamycin-SV, flavaspidic acid, bilirubin, and bromsulphthalein. Gut 1974; 15:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/11\">",
"      Chowdhury JR, Chowdhury NR, Moscioni AD, et al. Differential regulation by triiodothyronine of substrate-specific uridinediphosphoglucuronate glucuronosyl transferases in rat liver. Biochim Biophys Acta 1983; 761:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/12\">",
"      Rius M, Nies AT, Hummel-Eisenbeiss J, et al. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003; 38:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/13\">",
"      Cello JP. Acquired immunodeficiency syndrome cholangiopathy: spectrum of disease. Am J Med 1989; 86:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/14\">",
"      McCarty M, Choudhri AH, Helbert M, Crofton ME. Radiological features of AIDS related cholangitis. Clin Radiol 1989; 40:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/15\">",
"      Mendenhall CL, Anderson S, Weesner RE, et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984; 76:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/16\">",
"      Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20:594.",
"     </a>",
"    </li>",
"    <li>",
"     Stricker, BHCh. Drug-induced Hepatic Injury, Elsevier, Amsterdam 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/18\">",
"      Tandon BN, Tandon HD, Tandon RK, et al. An epidemic of veno-occlusive disease of liver in central India. Lancet 1976; 2:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/19\">",
"      Tandon BN, Joshi YK, Sud R, et al. Follow-up of survivors of epidemic veno-occlusive disease in India. Lancet 1984; 1:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/20\">",
"      Hall AJ, Harrington JM, Waterhouse JA. The Epping jaundice outbreak: a 24 year follow up. J Epidemiol Community Health 1992; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/21\">",
"      Bagla P, Kaiser J. India's spreading health crisis draws global arsenic experts. Science 1996; 274:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/22\">",
"      Fuchs M, Sanyal AJ. Sepsis and cholestasis. Clin Liver Dis 2008; 12:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/23\">",
"      Hojo M, Sano N, Takikawa H. Effects of lipopolysaccharide on the biliary excretion of bile acids and organic anions in rats. J Gastroenterol Hepatol 2003; 18:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/24\">",
"      Bolder U, Ton-Nu HT, Schteingart CD, et al. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology 1997; 112:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/25\">",
"      Welsh FK, Ramsden CW, MacLennan K, et al. Increased intestinal permeability and altered mucosal immunity in cholestatic jaundice. Ann Surg 1998; 227:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/26\">",
"      Dourakis SP, Sinani C, Deutsch M, et al. Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma. Eur J Gastroenterol Hepatol 1997; 9:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/27\">",
"      Walther MM, Johnson B, Culley D, et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol 1998; 159:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/28\">",
"      Karakolios A, Kasapis C, Kallinikidis T, et al. Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma. Clin Gastroenterol Hepatol 2003; 1:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/29\">",
"      Allardyce DB. Cholestasis caused by lipid emulsions. Surg Gynecol Obstet 1982; 154:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/30\">",
"      van Deventer SJ, ten Cate JW, Tytgat GN. Intestinal endotoxemia. Clinical significance. Gastroenterology 1988; 94:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/31\">",
"      Zimmerman HJ, Fang M, Utili R, et al. Jaundice due to bacterial infection. Gastroenterology 1979; 77:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/32\">",
"      Collins JD, Bassendine MF, Ferner R, et al. Incidence and prognostic importance of jaundice after cardiopulmonary bypass surgery. Lancet 1983; 1:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/33\">",
"      Dale O, Brown BR Jr. Clinical pharmacokinetics of the inhalational anaesthetics. Clin Pharmacokinet 1987; 12:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/34\">",
"      Faust TW, Reddy KR. Postoperative jaundice. Clin Liver Dis 2004; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/35\">",
"      Stratta RJ, Wood RP, Langnas AN, et al. Diagnosis and treatment of biliary tract complications after orthotopic liver transplantation. Surgery 1989; 106:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/36\">",
"      Betrosian A, Balla M, Kafiri G, et al. Reversal of liver failure in sickle cell vaso-occlusive crisis. Am J Med Sci 1996; 311:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/37\">",
"      Bond LR, Hatty SR, Horn ME, et al. Gall stones in sickle cell disease in the United Kingdom. Br Med J (Clin Res Ed) 1987; 295:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/38\">",
"      Charlotte F, Bachir D, N&eacute;nert M, et al. Vascular lesions of the liver in sickle cell disease. A clinicopathological study in 26 living patients. Arch Pathol Lab Med 1995; 119:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/39\">",
"      Reyes H. Review: intrahepatic cholestasis. A puzzling disorder of pregnancy. J Gastroenterol Hepatol 1997; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/40\">",
"      Shaw D, Frohlich J, Wittmann BA, Willms M. A prospective study of 18 patients with cholestasis of pregnancy. Am J Obstet Gynecol 1982; 142:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7065/abstract/41\">",
"      Leevy CB, Koneru B, Klein KM. Recurrent familial prolonged intrahepatic cholestasis of pregnancy associated with chronic liver disease. Gastroenterology 1997; 113:966.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3615 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7065=[""].join("\n");
var outline_f6_57_7065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISORDERS ASSOCIATED WITH UNCONJUGATED HYPERBILIRUBINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overproduction of bilirubin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Extravascular hemolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Extravasation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Intravascular hemolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Dyserythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Serum bilirubin concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bilirubin overproduction with coexisting liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Urobilinogen excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gallstones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Impaired hepatic bilirubin uptake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Impaired bilirubin conjugation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DISORDERS ASSOCIATED WITH CONJUGATED HYPERBILIRUBINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Biliary obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intrahepatic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Viral hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Alcoholic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Nonalcoholic steatohepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Sepsis and low perfusion states",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Liver infiltration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Inherited diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Total parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Postoperative patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Following organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Intrahepatic cholestasis of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - End-stage liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hepatocellular injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3615\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3615|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/40/36494\" title=\"algorithm 1A\">",
"      Classification jaundice I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/37/19038\" title=\"algorithm 1B\">",
"      Classification jaundice II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3615|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/16/37127\" title=\"figure 1\">",
"      Impaired bilirubin excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/7/12415\" title=\"figure 2\">",
"      Bilirubin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/51/31536\" title=\"figure 3\">",
"      Bilirubin in hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3615|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/55/28541\" title=\"table 1\">",
"      Classification of jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/11/19644\" title=\"table 2\">",
"      Dx extrahepatic cholestasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/58/39852\" title=\"table 3\">",
"      Dx intrahepatic cholestasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/21/32093\" title=\"table 4\">",
"      Hepatocellular jaundice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=related_link\">",
"      AIDS cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9718?source=related_link\">",
"      Approach to the patient with postoperative jaundice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=related_link\">",
"      Bilirubin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=related_link\">",
"      Causes of neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36294?source=related_link\">",
"      Clinical aspects of serum bilirubin determination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6201?source=related_link\">",
"      Crigler-Najjar syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2842?source=related_link\">",
"      Hepatic manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=related_link\">",
"      Hepatotoxicity due to herbal medications and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=related_link\">",
"      Intrahepatic cholestasis of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=related_link\">",
"      Management of the short bowel syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44565?source=related_link\">",
"      Mirizzi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/28/21953?source=related_link\">",
"      Patient information: Gilbert&rsquo;s syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/17/34066?source=related_link\">",
"      Patient information: Jaundice in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_57_7066="Treatment of myasthenia gravis";
var content_f6_57_7066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of myasthenia gravis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/57/7066/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/57/7066/contributors\">",
"     Shawn J Bird, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/57/7066/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/57/7066/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/57/7066/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/57/7066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/57/7066/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/57/7066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis (MG), once a uniformly disabling and even fatal disorder, can be managed effectively with current therapeutic strategies. Many patients can even achieve sustained remission. The therapeutic approach has certain general principles, but it is highly individualized for each patient. It depends upon the age of the patient, the severity of the disease, particularly dictated by respiratory or bulbar involvement, and the pace of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the general treatment of MG. Detailed reviews of chronic immunomodulating therapies for MG and thymectomy for MG are found separately. Myasthenic crisis and the treatment of ocular MG and MG in pregnancy are also discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link\">",
"     \"Thymectomy for myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36567?source=see_link\">",
"     \"Management of myasthenia gravis in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=see_link\">",
"     \"Ocular myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four basic therapies used to treat MG:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptomatic treatments (anticholinesterase agents)",
"     </li>",
"     <li>",
"      Chronic immunomodulating treatments (glucocorticoids and other immunosuppressive drugs)",
"     </li>",
"     <li>",
"      Rapid immunomodulating treatments (plasmapheresis and intravenous immune globulin)",
"     </li>",
"     <li>",
"      Surgical treatment (thymectomy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms can be treated with acetylcholinesterase inhibitors (also called anticholinesterase medications). These medications are all that is ever needed for some patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     Pyridostigmine",
"    </a>",
"    bromide (Mestinon) is the main cholinesterase inhibitor currently in use. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Symptomatic treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, most patients with MG require some form of immunotherapy at some point in their illness, if not indefinitely. Even when immunotherapeutic drugs are used, it is common to continue the use of anticholinesterase medications in order to reduce the dosage of immunosuppressive drugs and therefore minimize their adverse effects. Balancing the improvement of MG symptoms with the side effects of the immunotherapeutic agents is always a challenge for the clinician and patient.",
"   </p>",
"   <p>",
"    Commonly used immunotherapeutic drugs in MG are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil. In some circumstances, particularly in those with refractory MG, other agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , monthly pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    may be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasmapheresis and intravenous immune globulin (IVIG) are rapid immunotherapies that work quickly but have a short duration of action. These are usually reserved for certain situations, such as myasthenic crisis, preoperatively before thymectomy, as a \"bridge\" while initiating slower acting immunotherapies, or as an adjuvant to other immunotherapeutic medications in patients with refractory MG. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Rapid immunotherapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many experts believe that thymectomy is beneficial in those patients less than age 60 who have generalized MG without thymoma, although there are no prospective randomized, blinded, controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/5\">",
"     5",
"    </a>",
"    ]. However, it generally takes years for the benefits of thymectomy to accrue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link\">",
"     \"Thymectomy for myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The time of onset of clinical effect of each of these therapies for MG varies considerably (",
"    <a class=\"graphic graphic_table graphicRef70721 \" href=\"UTD.htm?4/56/5004\">",
"     table 1",
"    </a>",
"    ). This plays a large role, in addition to the pace and severity of the disease, in choosing the appropriate therapy for a given patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial therapy for most patients with myasthenia gravis (MG) is an oral anticholinesterase (ie, acetylcholinesterase inhibitor) medication, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    bromide. Acetylcholinesterase inhibitors retard the degradation of acetylcholine (ACh) that occurs by enzymatic hydrolysis in the neuromuscular junction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/6\">",
"     6",
"    </a>",
"    ]. As a result, the effect of ACh is prolonged, leading to a variable improvement in strength.",
"   </p>",
"   <p>",
"    Acetylcholinesterase inhibitors provide marked improvement in some patients and little or none in others. Often the symptom improvement may be mixed, with marked improvement in some symptoms but not others (for example, resolution of neck weakness and ptosis with persistence of diplopia). In general, limb and bulbar symptoms (dysphagia, fatigable chewing, and dysarthria) respond better to anticholinesterase drugs than the ocular manifestations (ptosis and diplopia). Diplopia is particularly resistant to these medications in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acetylcholinesterase inhibitors are the first line of treatment due to their safety and ease of use.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     Pyridostigmine",
"    </a>",
"    (Mestinon) is the usual choice.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     Neostigmine",
"    </a>",
"    is available but not commonly used. Acetylcholinesterase inhibitors provide only symptomatic therapy and are usually not sufficient in generalized MG. Nonetheless, in some patients this is the only therapy ever needed for good control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pyridostigmine dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     Pyridostigmine",
"    </a>",
"    has a rapid onset of action (15 to 30 minutes) with peak action at about two hours, and its effects last for three to four hours, sometimes longer. Despite its short duration of action, some patients can use it quite effectively with doses every six hours or three time a day. Others need a dose every three hours to maintain symptomatic benefit.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For adults and older adolescents, a common starting dose is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"       pyridostigmine",
"      </a>",
"      30 mg three times a day. The dose is then titrated by its effect. The maximal dose and frequency is usually 120 mg every four hours while awake. An occasional patient will need to take a dose every three hours, but never at shorter intervals. Almost all adult patients require a total daily dose of &le;960 mg, divided into four to eight doses.",
"     </li>",
"     <li>",
"      For children and younger adolescents, the initial dose is 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four to six hours [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/8,9\">",
"       8,9",
"      </a>",
"      ], up to a total daily dose of 7",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     Pyridostigmine",
"    </a>",
"    is available as scored 60 mg tablets and as a liquid formulation. Pyridostigmine is also available in an intravenous preparation and can be given in patients who cannot take oral drugs. This is usually in the setting of myasthenic crisis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It should be kept in mind that no fixed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    dosing schedule fits all patients. Most adult patients who respond do so in the range of 60 to 90 mg every four to six hours while awake. Some adults require as much as 120 mg every three to four hours while awake. Doses above this are rarely beneficial and are usually limited by the bothersome cholinergic side effects (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Side effects'",
"    </a>",
"    below). When a patient has significant persistent weakness despite the use of pyridostigmine in sufficient doses, or the side effects preclude effective dosing, then immunotherapy is generally warranted.",
"   </p>",
"   <p>",
"    The dose regimen used must be thoughtfully individualized to get symptomatic benefits and to limit unnecessary cholinergic side effects. As an example, many patients only have significant symptoms in the evening. An adult patient might do well with no",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    until a lunchtime dose of 60 mg followed four hours and eight hours later by 90 mg. Those who have trouble chewing or mild dysphagia might benefit by taking a dose 30 minutes before a meal. There are numerous combinations that work best for an individual patient, based upon the severity of symptoms, the response to pyridostigmine, and toleration of side effects. Medications that alleviate some of the cholinergic side effects of pyridostigmine may also be helpful (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Alleviating side effects'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A long-acting formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    (Mestinon TS, 180 mg) is also available. It is used as a bedtime dose in patients with persistent, severe weakness upon awakening. Most patients, however, do better after a night's sleep, and those with mild weakness upon awakening may do as well by taking a standard pyridostigmine dose at that time. Long-acting pyridostigmine is not a good choice for daytime use because its variable release and delayed absorption make it difficult to provide a consistent effect and to regulate the overall pyridostigmine dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    are mostly due to the cholinergic properties of the drug. These cholinergic effects can be dose-limiting in many patients. The most bothersome muscarinic side effects include abdominal cramping and diarrhea. Others are increased salivation and bronchial secretions, nausea, sweating, and bradycardia. Nicotinic side effects are also frequent and include fasciculations and muscle cramping. However, these are usually less bothersome than the gastrointestinal effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Alleviating side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    with food can help to reduce bothersome gastrointestinal side effects. Muscarinic side effects can be controlled in many patients with the use of anticholinergic drugs that have little or no effect at the nicotinic receptors (ie, do not produce increased weakness). These include the following agents:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"       Glycopyrrolate",
"      </a>",
"      1 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/4/14404?source=see_link\">",
"       Propantheline",
"      </a>",
"      15 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/9/29846?source=see_link\">",
"       Hyoscyamine",
"      </a>",
"      sulfate 0.125 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These anticholinergic drugs can be taken prophylactically three times a day or, alternatively, with each",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    dose.",
"   </p>",
"   <p>",
"    Prominent diarrhea can be reduced by the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    (Imodium) or diphenoxylate hydrochloride-atropine sulfate (Lomotil) with or without other anticholinergic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cholinergic crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential major side effect of excessive anticholinesterase medication is weakness, which can be difficult to distinguish from worsening MG. This paradoxical weakening with anticholinesterase medications is called \"cholinergic crisis.\" However, cholinergic crisis is rarely if ever seen with dose limitation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    to &le;120 mg every three hours, or a total daily dose of &le;960 mg. Cholinergic crisis is so rare that it should not be the presumed cause of increasing weakness unless the doses taken are known to significantly exceed this range. Otherwise, even in the presence of cholinergic side effects, it should be assumed that the patient's underlying MG is worsening and appropriate treatment should be initiated.",
"   </p>",
"   <p>",
"    Some have advocated the use of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    (Tensilon) test to determine if there is too much or too little anticholinesterase effect in this setting, but this has not proved to be reliable and is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of myasthenia gravis\", section on 'Tensilon test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHRONIC IMMUNOTHERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second therapeutic modality in MG is the administration of immunomodulating agents. Glucocorticoids are widely used as well as other agents, most commonly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . The onset of action varies considerably, and this plays a role in the choice of therapy (",
"    <a class=\"graphic graphic_table graphicRef70721 \" href=\"UTD.htm?4/56/5004\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The administration of moderate or high doses of glucocorticoids leads to remission in about 30 percent of patients and marked improvement in another 50 percent. The onset of benefit generally begins within two to three weeks. However, a transient deterioration occurs in up to 50 percent of patients with MG when high-dose glucocorticoids are started, usually occurring 5 to 10 days after the initiation and lasting around five or six days. For this reason, glucocorticoids are most often started in high doses only in hospitalized patients who are receiving concurrent plasmapheresis or intravenous immune globulin (IVIG) for myasthenic crisis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To avoid the transient worsening, an outpatient glucocorticoid dose escalation regimen works quite effectively.",
"   </p>",
"   <p>",
"    A detailed discussion of glucocorticoids and other immunomodulating agents for MG as well as the data supporting their use is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RAPID IMMUNOTHERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid therapies used in MG are also immunomodulating but are distinct because of their quick onset, transient benefit, and their use in select situations. Both plasmapheresis and intravenous immune globulin (IVIG) start to work quickly (over days), but the benefits are only short term (weeks). These therapeutic modalities are used most often in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myasthenic crisis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"       \"Myasthenic crisis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Preoperatively before thymectomy or other surgery (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link\">",
"       \"Thymectomy for myasthenia gravis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      As a \"bridge\" to slower acting immunotherapies (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Bridge therapy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Periodically to maintain remission in patients with MG that is not well controlled despite the use of chronic immunomodulating drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis (plasma exchange) directly removes acetylcholine receptor (AChR) antibodies from the circulation. Clinical improvement with plasmapheresis roughly correlates with the reduction in antibody levels, as illustrated by the following reports [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In five patients with refractory MG (moderate to severe disability despite treatment with thymectomy, high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and cholinesterase inhibitors), plasmapheresis combined with prednisone and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      therapy produced clinical improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/10\">",
"       10",
"      </a>",
"      ]. Serial determinations of serum AChR antibody titers showed a decline to a mean of 21 percent of the baseline levels concurrently with improved strength. Clinically improved patients maintained lowered AChR titers, whereas clinical relapses were associated with a rebound in AChR titers.",
"     </li>",
"     <li>",
"      In seven patients with acquired MG who had elevated serum AChR antibody titers there was an inverse association between improvement of muscle strength and fall of anti-AChR titers [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/11\">",
"       11",
"      </a>",
"      ]. There was a minimum time lag of two days for the clinical response to plasmapheresis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The beneficial clinical effect of plasmapheresis is usually seen within days, but the benefit typically lasts only three to six weeks. In addition, the AChR antibody levels rebound within weeks if no concurrent immunotherapy (eg, glucocorticoids) is used.",
"   </p>",
"   <p>",
"    Plasmapheresis is an established treatment for seriously ill patients in the midst of myasthenic crisis. The evidence supporting its use in this situation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link&amp;anchor=H8#H8\">",
"     \"Myasthenic crisis\", section on 'Plasmapheresis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasmapheresis is not a useful long-term treatment, since the need for repeated exchanges often leads to problems with venous access (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Complications'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A potential innovation, not widely adapted, is the use of plasmapheresis with an immunosorbent column consisting of staphylococcal protein A [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/13\">",
"     13",
"    </a>",
"    ]. This technique more efficiently removes IgG, the immunoglobulin that includes those against acetylcholine receptors in MG.",
"   </p>",
"   <p>",
"    In a further refinement, a Japanese group has designed an acetylcholine receptor antibody-specific immunosorbent column using a peptide isolated from the acetylcholine receptor of Torpedo Californica, called Medisorba MG. This column is targeted to remove the blocking acetylcholine receptor antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/14\">",
"     14",
"    </a>",
"    ]. This technique is approved for use in Japan where it has produced clinical improvement in 78 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/15\">",
"     15",
"    </a>",
"    ]. Its potential advantages include selective removal of anti-AChR antibodies without removing other useful immunoglobulins from the plasma and no requirement for albumin replacement. However, it has limited clinical use and has not yet been shown to be superior to plasmapheresis with regard to efficacy, cost, and safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Course of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A typical course of treatment consists of five exchanges (3 to 5 L of plasma each) over 7 to 14 days. The replacement fluid is albumin when used in the treatment of MG. Although done daily in some circumstances, exchanges done every other day are probably more effective in reducing the antibody levels due to the time it takes for the extravascular immunoglobulin to re-equilibrate after each plasma exchange. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeated plasmapheresis invariably leads to inadequate peripheral venous access and then requires placement of a large bore, double lumen central catheter (subclavian or internal jugular). Significant chronic catheter complications often result, such as infection and thrombosis.",
"   </p>",
"   <p>",
"    In addition to the catheter complications, plasmapheresis can also produce other adverse effects including bleeding, hypotension, cardiac arrhythmias, muscle cramps, and a toxic reaction to the citrate used in the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=see_link\">",
"     \"Complications of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IVIG) is pooled immunoglobulin from thousands of donors. The mechanism of action for IVIG in MG is uncertain. As with plasmapheresis, the effect of IVIG is seen typically in less than a week, and the benefit can last for three to six weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link&amp;anchor=H7#H7\">",
"     \"General principles in the use of immune globulin\", section on 'Mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IVIG is used in the same setting as plasmapheresis to quickly reverse an exacerbation of myasthenia. The limited evidence supporting its use in this situation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link&amp;anchor=H9#H9\">",
"     \"Myasthenic crisis\", section on 'Intravenous immune globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IVIG also offers an alternative to plasmapheresis or multiple immunosuppressive agents in select patients with refractory MG, as a preoperative treatment before thymectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], or as a \"bridge\" to slower acting immunotherapies.",
"   </p>",
"   <p>",
"    As with myasthenic crisis, there are limited data regarding the effectiveness of IVIG for MG without crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind trial, 51 patients with mild to moderate MG and worsening weakness were randomly assigned to IVIG (2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      given over two days) or placebo (an equivalent volume of dextrose 5 percent in water) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/21\">",
"       21",
"      </a>",
"      ]. Exclusion criteria included respiratory distress, vital capacity &lt;1 liter, and severe swallowing difficulty. Patients treated with IVIG showed a modest but statistically significant improvement compared with placebo in the Quantitative Myasthenia Gravis (QMG) Score for disease severity at day 14. The improvement persisted but failed to achieve statistical significance at day 28. In subgroup analysis, IVIG treatment was associated with clinically and statistically significant improvement in patients with more severe disease at study onset (QMG &gt;10.5), but no improvement was observed in patients with milder disease (QMG &lt;10.5).",
"     </li>",
"     <li>",
"      A double-blind randomized trial compared treatment with IVIG versus plasmapheresis for 81 adults with MG and worsening weakness requiring change in therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/22\">",
"       22",
"      </a>",
"      ]. At baseline, 59 percent of patients had mild disease, 40 percent had moderate disease, while only 1 percent had severe disease. Patients who had a flare producing moderate to severe disease (a QMG score &gt;10.5) were treated. At day 14, a similar proportion of patients assigned to IVIG and plasmapheresis had improved (69 versus 65 percent) and the duration of improvement was also similar with longer follow-up.",
"     </li>",
"     <li>",
"      In earlier observational reports, IVIG was effective in nearly 70 to 75 percent of patients with MG [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dose and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total dose of IVIG is 2",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    usually over two to five days. Spreading the dose over more days is preferable in those who have renal disease, congestive heart failure, or are elderly.",
"   </p>",
"   <p>",
"    The side effects of IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/25,26\">",
"     25,26",
"    </a>",
"    ] are most commonly mild and are related to the infusion rate. These include headache, chills, dizziness, and fluid retention. Other uncommon complications include aseptic meningitis, acute renal failure, thrombotic events, and anaphylaxis.",
"   </p>",
"   <p>",
"    The acute nephrotoxicity that occurs in some patients appears to be related to the high sucrose content of some preparations of IVIG; the risk is increased with underlying renal insufficiency. Anaphylaxis has been associated with IgA deficiency; however, it is rarely seen in patients treated for autoimmune neuromuscular diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/26\">",
"     26",
"    </a>",
"    ]. Thrombotic events associated with IVIG use include myocardial infarction, stroke, and pulmonary embolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     THERAPEUTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above discussion details the various options in the treatment of the patient with MG along with certain general principles that can act as a framework for treating patients (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Overview'",
"    </a>",
"    above). However, it should always be kept in mind that the treatment of MG is highly individualized for each patient. Treatment choices depend on the age of the patient, the severity of the disease, particularly the presence of bulbar or respiratory symptoms, and the pace of progression.",
"   </p>",
"   <p>",
"    In addition, special circumstances can dictate different approaches to treat MG. This section will review the approach in adults with generalized MG and ocular MG, adults over 60 years of age, and children. The treatment of MG in pregnancy and approach to severe MG exacerbations including myasthenic crisis is mentioned below but is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36567?source=see_link\">",
"     \"Management of myasthenia gravis in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Generalized myasthenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in most adult patients with mild or moderate disease is symptomatic therapy in the form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    bromide (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Symptomatic treatment'",
"    </a>",
"    above). Those with severe disease, or rapidly worsening disease, should be treated much like those in myasthenic crisis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    ) using rapid therapies (ie, intravenous immunoglobulin or plasmapheresis) followed by longer-acting immunotherapies (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\"",
"    </a>",
"    ) such as glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    When starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    for an older adolescent or adult, we begin at 30 mg",
"    <span class=\"nowrap\">",
"     (1/2",
"    </span>",
"    tab) with meals three times a day for two to three days to assess the cholinergic side effects (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Pyridostigmine dosing'",
"    </a>",
"    above). For those with excessive cholinergic side effects we add an agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    1 mg with each pyridostigmine dose) to block those bothersome symptoms. For those who tolerate the pyridostigmine well, with or without anticholinergics, we increase the dose by 30 mg increments until we get to a good therapeutic effect or are limited by side effects. The maximum dose is usually 120 mg every four hours while awake. An occasional patient may need to take it every three hours while awake. For those with bothersome symptoms upon awakening in the morning, we use a long-acting form of pyridostigmine (Mestinon TS 180 mg) at bedtime.",
"   </p>",
"   <p>",
"    For children and younger adolescents, the initial dose is 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four to six hours (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Pyridostigmine dosing'",
"    </a>",
"    above). This can be titrated up slowly based on the therapeutic response and side-effects. The maximal daily dose is 7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per 24 hours divided in five to six doses.",
"   </p>",
"   <p>",
"    For those patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    alone whose symptoms are under good control or in remission, we simply follow their clinical course. Thymectomy should be considered in all adult patients under age 60 as well (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link\">",
"     \"Thymectomy for myasthenia gravis\"",
"    </a>",
"    ). Although there are some patients who do well long-term on pyridostigmine alone, most patients with generalized MG ultimately require some form of immunotherapy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Addition of immunomodulating agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;An immunotherapeutic agent is usually required for patients who remain significantly symptomatic on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    , or who become symptomatic again after a temporary response to pyridostigmine. The choice of agent &ndash; most often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &ndash; depends on many factors. These include the relative contraindications to glucocorticoids (such as diabetes or advanced age), liver disease (precluding azathioprine use), renal disease (precludes cyclosporine use), or leukopenia (problematic for both azathioprine and mycophenolate). The desired time for response onset also is a factor (",
"    <a class=\"graphic graphic_table graphicRef70721 \" href=\"UTD.htm?4/56/5004\">",
"     table 1",
"    </a>",
"    ), varying from two to three weeks with prednisone to 6 to 12 months with azathioprine. Cost is another important consideration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In young adult patients, particularly those of child-bearing potential, we favor the use of glucocorticoids. We often can get a good response with high doses initially and then maintain that response after a slow taper down to low doses (on the order of 10 mg daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ). We also use glucocorticoids in older individuals who need a relatively quick response to immunotherapy and then try to add another agent (most often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil) to replace the glucocorticoids for the long term.",
"   </p>",
"   <p>",
"    There are a number of reasonable approaches to starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , including daily and alternate day dosing. Dosing of glucocorticoids, including dose escalation and tapering, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who cannot be tapered to low doses without clinical relapse or in those patients where long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is not desirable, even at low doses, another immunomodulating agent is substituted.",
"   </p>",
"   <p>",
"    We add a glucocorticoid-sparing agent, or glucocorticoid replacement, when we are down to the lowest dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    that will maintain a reasonable clinical response. Effective glucocorticoid-sparing agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link&amp;anchor=H7#H7\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\", section on 'Glucocorticoid (steroid) sparing agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the minimum time to onset of clinical response for the added immunotherapy (eg, often 12 months or more for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) has passed, we then slowly taper",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    to as low a dose as can be achieved, preferably none at all. After the glucocorticoids have been tapered, we then try to taper",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    . Many, but certainly not all, patients can be minimally symptomatic or in remission on one immunotherapy agent alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Bridge therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients with MG in whom it is especially desirable to avoid glucocorticoids (such as those with poorly controlled diabetes) or for those who are not successfully weaned to lower doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , we often use monthly courses of IVIG until the more slowly acting immunotherapy takes effect. Monthly plasmapheresis is an alternative to IVIG. However, venous access problems develop with frequent use of plasmapheresis, making it less practical than IVIG for use as a bridge therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60761455\">",
"    <span class=\"h3\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a small cohort of patients with generalized MG who are refractory to, or are limited by the specific toxicities of, the first-line immunotherapies (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ). Some require unacceptably high doses of glucocorticoids despite concurrent use of these agents. In these refractory patients, monthly IVIG or the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is often beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link&amp;anchor=H5661854#H5661854\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Need for thymectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In parallel with symptomatic treatment and immunotherapeutic agents for MG, we consider thymectomy because of its potential longer-term benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link\">",
"     \"Thymectomy for myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with thymoma clearly need surgical treatment. However, the need for thymectomy is less certain in those with nonthymomatous tissue. We advise such patients that the likelihood of medication-free remission is about twice as high with thymectomy than without, and that the likelihood of becoming asymptomatic is about one and a half times as high with thymectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/5\">",
"     5",
"    </a>",
"    ]. We also emphasize that the benefit of thymectomy is delayed and accrues over several years postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link&amp;anchor=H3#H3\">",
"     \"Thymectomy for myasthenia gravis\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We advocate thymectomy as soon as the patient's degree of weakness is sufficiently controlled to permit surgery, if the patient is amenable to that surgery. We also prefer to have patients on relatively low doses of glucocorticoids, if possible, to avoid postoperative problems with wound healing.",
"   </p>",
"   <p>",
"    For patients with preoperative bulbar or respiratory symptoms, we try to defer surgery until they are reasonably well controlled. We administer IVIG or perform a series of plasma exchanges one or two weeks before surgery, if these respiratory or bulbar symptoms persist. The exact timing of surgery and what techniques are appropriate are issues not settled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ocular myasthenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elements of treatment for ocular myasthenia gravis (OMG) are the same as with generalized MG. However, differences in the symptomatology, disability, and prognosis lead to some differences in the treatment approach for these patients. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=see_link&amp;anchor=H22#H22\">",
"     \"Ocular myasthenia gravis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Age 60 and over",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not routinely suggest thymectomy in patients over 60 years of age, unless a thymoma is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link&amp;anchor=H6#H6\">",
"     \"Thymectomy for myasthenia gravis\", section on 'Patient age and severity of disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=see_link\">",
"     \"Clinical presentation and management of thymoma and thymic carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are no firm data to support a strict age limit for this surgical therapy, many feel that thymectomy is less likely to be beneficial in this age group due to the high incidence of thymic involution and an increased operative risk due to comorbidities. We use age 60 as a rough rule of thumb, but this is moderated by the patient's overall health, functional age, and the patient's wishes after reviewing the issues with him or her. Despite the reluctance at many centers to perform this surgery on older patients with MG, there is some evidence that patients over age 60 may benefit from the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other than a tendency to use glucocorticoids more sparingly in this group, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil does not differ from that detailed above. Due to the potential renal side effects, we do not commonly use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in these patients. There are few studies that look at the treatments in this particular age group. However, the usefulness of immunotherapy is supported by a study of outcome at one year or longer in 149 patients with disease onset after age 60 who were treated with azathioprine with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/28\">",
"     28",
"    </a>",
"    ]. Better outcomes and fewer side effects were observed when prednisone was avoided or was combined with azathioprine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with adults, the treatment of children with MG should be individualized based on the severity and pace of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/8,9,29\">",
"     8,9,29",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     Pyridostigmine",
"    </a>",
"    is the first line of therapy (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Pyridostigmine dosing'",
"    </a>",
"    above). If anticholinesterase medications are not sufficient, plasmapheresis or intravenous immune globulin may be used, but the benefits are transient.",
"   </p>",
"   <p>",
"    Glucocorticoids are generally limited to severe disease that is unresponsive to these interventions. Glucocorticoids retard bone growth, increase the risk of adult osteoporosis, and are especially problematic for chronic use in children.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    have been used successfully in juvenile MG [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/9,29\">",
"     9,29",
"    </a>",
"    ], but concerns about serious adverse effects, including impaired fertility and the late development of malignancy, are of even greater concern than in adults.",
"   </p>",
"   <p>",
"    As a long-term treatment for MG, thymectomy has been performed successfully and with low morbidity in children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/30\">",
"     30",
"    </a>",
"    ]. Thymectomy is a widely accepted option for peripubertal and postpubertal children with generalized MG who have positive acetylcholine receptor antibodies or who are seronegative [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/8,9,29-31\">",
"     8,9,29-31",
"    </a>",
"    ]. The rates of improvement and remission seen in uncontrolled series appear to be similar to that reported in adults after thymectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/30\">",
"     30",
"    </a>",
"    ]. Thorascopic thymectomy, potentially a more acceptable treatment in this age group, has been used successfully in a small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/32\">",
"     32",
"    </a>",
"    ]. The likelihood of improvement or remission after a single procedure (thymectomy) compared with long-term immunotherapy makes this option a reasonable consideration in all children who have more than mild disease. No significant deleterious consequences of removing the thymus in childhood have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to adults with MuSK antibody-positive MG (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link&amp;anchor=H7669765#H7669765\">",
"     \"Thymectomy for myasthenia gravis\", section on 'MuSK antibody-positive myasthenia'",
"    </a>",
"    ), children with MuSK-positive MG have not been shown to benefit from thymectomy. Therefore, thymectomy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for this group. The role of thymectomy in prepubertal children remains controversial. This group has a higher incidence of spontaneous remission and is also more likely to be seronegative, making confirmation of the diagnosis more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/8,29\">",
"     8,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical outcome in childhood MG varies with age of onset, race, and sex [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/33\">",
"     33",
"    </a>",
"    ]. White children with prepubertal onset have the best prognosis. The spontaneous remission rate is 44 percent in these children, and they respond well to early thymectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pregnancy and the neonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy has a variable effect on the course of MG. It does not worsen the long-term outcome, but the MG may worsen during the course of pregnancy. The first trimester and the month postpartum are the periods of highest risk of exacerbation.",
"   </p>",
"   <p>",
"    The management of myasthenia in pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36567?source=see_link\">",
"     \"Management of myasthenia gravis in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transient neonatal MG develops in 10 to 20 percent of infants born to myasthenic mothers due to transplacental passage of antiacetylcholine receptor antibodies. Neonatal myasthenia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link\">",
"     \"Neuromuscular junction disorders in newborns and infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Myasthenic crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenic crisis is a life-threatening condition, and it is characterized by neuromuscular respiratory failure. Severe bulbar weakness that produces dysphagia and aspiration often complicates the respiratory failure. Patients in myasthenic crisis typically experience increasing generalized weakness as a warning, although occasionally a patient will present with respiratory insufficiency out of proportion to their limb or bulbar weakness.",
"   </p>",
"   <p>",
"    The evaluation and treatment of myasthenic crisis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Drugs that may exacerbate myasthenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some medications may cause a significant",
"    <strong>",
"     increase",
"    </strong>",
"    in weakness in patients with MG (",
"    <a class=\"graphic graphic_table graphicRef62302 \" href=\"UTD.htm?11/61/12254\">",
"     table 2",
"    </a>",
"    ). These include aminoglycoside antibiotics, beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/34\">",
"     34",
"    </a>",
"    ]. A number of other drugs may unmask or exacerbate MG, particularly the neuromuscular blocking agents used during anesthesia, which can lead to prolonged postoperative weakness and ventilator dependence.",
"   </p>",
"   <p>",
"    In a literature review of drug-induced myasthenia, the drugs that were most likely to have a negative impact on MG were those used in the treatment of the disease, including [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"     </li>",
"     <li>",
"      Overuse of anticholinesterase drugs",
"     </li>",
"     <li>",
"      Anesthesia and neuromuscular blockers for thymectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aminoglycoside-related postoperative respiratory depression caused the greatest frequency of drug-induced neuromuscular blockade.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     Penicillamine",
"    </a>",
"    , used in other autoimmune diseases, induces an autoimmune myasthenic syndrome in approximately 1 percent of cases. It simulates primary MG in that it can induce ocular or generalized weakness with the production of acetylcholine receptor antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The myasthenic symptoms eventually resolve after the penicillamine is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15654?source=see_link&amp;anchor=H9#H9\">",
"     \"Differential diagnosis of myasthenia gravis\", section on 'Penicillamine-induced myasthenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following drugs warrant special concern in patients with MG (",
"    <a class=\"graphic graphic_table graphicRef62302 \" href=\"UTD.htm?11/61/12254\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aminoglycosides should be avoided and only used if absolutely necessary with close monitoring.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"       Telithromycin",
"      </a>",
"      has been associated with exacerbations or unmasking of MG in several case reports, often within two hours of the first dose [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. A black box warning has been added to the drug label stating that telithromycin should not be used in patients with MG. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H12#H12\">",
"       \"Azithromycin, clarithromycin, and telithromycin\", section on 'Warnings about telithromycin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuromuscular blocking agents may be necessary for anesthesia or intubation, but their use delays emergence from anesthesia, recovery of muscle strength, and weaning from mechanical ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/40\">",
"       40",
"      </a>",
"      ]. These drugs should be judiciously titrated if used.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      and procaine may cause worsening if injected intravenously.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      is relatively contraindicated because magnesium has a significant inhibitory effect on acetylcholine release.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       Penicillamine",
"      </a>",
"      and interferon-alpha should be avoided in patients with MG because they can induce MG.",
"     </li>",
"     <li>",
"      Fluoroquinolone antibiotics should be used with caution.",
"     </li>",
"     <li>",
"      All beta blockers should be used with caution.",
"     </li>",
"     <li>",
"      All glucocorticoids at high doses may cause exacerbation of MG symptoms during early stages of treatment.",
"     </li>",
"     <li>",
"      Among anticonvulsants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      have been rarely reported to exacerbate MG, but these drugs may be used if needed. Experimental evidence suggests that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/54/13158?source=see_link\">",
"       ethosuximide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      may cause increased weakness, but there are no clinical reports.",
"     </li>",
"     <li>",
"      Central nervous system depressants, opioids, and muscle relaxants may increase MG symptoms when these agents are used concurrently or given in high doses.",
"     </li>",
"     <li>",
"      Statin treatment may be associated with MG, as suggested by a few case reports and case series [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/41-45\">",
"       41-45",
"      </a>",
"      ] that describe a total of 12 patients with new or worsening MG in the context of extensive use of these drugs. Exacerbation of pre-existing MG within a few months of starting statin therapy was reported in eight patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/43-45\">",
"       43-45",
"      </a>",
"      ], including six from a single-center retrospective study of 170 patients with MG who were surveyed about statin treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/45\">",
"       45",
"      </a>",
"      ]. Symptoms of de novo MG developed within weeks of starting statins in four patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Unmasking of subclinical MG due to statin-related myotoxicity appeared to be the most likely explanation for some of new cases, and the coincidental occurrence of autoimmune MG with statin therapy was also a consideration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A good rule-of-thumb in generalized MG is to assume that any medication may exacerbate MG and to watch for worsening following the introduction of a new medication. Whether the association with clinical worsening of MG is coincidental or casually related may require withdrawal from the medication and a rechallenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with generalized MG who develop respiratory infections are at increased risk of myasthenic exacerbations and respiratory compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/46\">",
"     46",
"    </a>",
"    ]. This increased risk may be shared by patients with ocular MG of more recent onset (less than three years), because they are still at risk of progressing to generalized disease. In contrast, patients with stable ocular MG of three or more years duration are much less likely to develop generalized disease and therefore are not considered to be at increased risk of myasthenic exacerbations or respiratory compromise.",
"   </p>",
"   <p>",
"    Current guidelines recommend annual seasonal influenza vaccination for all individuals receiving immunosuppressive therapy, and for those with neurologic conditions, including neuromuscular disorders such as generalized MG, or ocular MG within three years of onset, that can potentially compromise the handling of respiratory secretions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A population-based study suggests that the inactivated (intramuscular) influenza vaccine is safe in adults with MG [",
"    <a class=\"abstract\" href=\"UTD.htm?6/57/7066/abstract/47\">",
"     47",
"    </a>",
"    ]. Furthermore, inactivated vaccines (eg, pneumococcal and intramuscular influenza vaccines) generally are considered safe in adults or children with immunocompromising conditions, while live vaccines generally are avoided. Thus, patients being treated with immunotherapy for MG should",
"    <strong>",
"     not",
"    </strong>",
"    receive the live-attenuated (intranasal) influenza vaccine.",
"   </p>",
"   <p>",
"    The pneumococcal vaccine is recommended for all individuals with chronic pulmonary conditions and for those receiving immunosuppressive therapy. While MG does not usually result in chronic pulmonary disease, we suggest pneumococcal vaccination for all individuals with generalized MG, and for those with ocular MG who are within three years of onset, because of the risk that infection may trigger an MG exacerbation or crisis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/14/14562?source=see_link\">",
"       \"Patient information: Myasthenia gravis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The four basic therapies for MG include symptomatic treatments (anticholinesterase agents), chronic immunotherapies (glucocorticoids and other immunosuppressive drugs), rapid immunotherapies (plasma exchange and intravenous immune globulin [IVIG]), and thymectomy. The time of onset of clinical effect of each of these therapies for MG varies considerably (",
"      <a class=\"graphic graphic_table graphicRef70721 \" href=\"UTD.htm?4/56/5004\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment with acetylcholinesterase inhibitors as the first line of treatment for symptomatic MG (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"       Pyridostigmine",
"      </a>",
"      is the most widely used choice. For adults and older adolescents, a typical starting dose is 30 mg three times a day. For children and younger adolescents, the initial dose is 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four to six hours. The dose of pyridostigmine is then titrated by its effect. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Symptomatic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with MG will need some form of immunotherapy in addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"       pyridostigmine",
"      </a>",
"      . We recommend adding immunotherapy for patients who remain significantly symptomatic on pyridostigmine, or who become symptomatic after a temporary response to pyridostigmine (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      are the most widely used (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Chronic immunotherapies'",
"      </a>",
"      above). This approach is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link\">",
"       \"Chronic immunomodulating therapies for myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasmapheresis (with plasma exchange) and IVIG work quickly but have a short duration of action. In addition to treatment of myasthenic crisis, these rapid therapies are useful in presurgical treatment of moderate to severe MG. They are also used as a \"bridge\" when initiating slower acting immunotherapies, and as periodic adjuvants to other immunotherapeutic medications in refractory MG. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Rapid immunotherapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest thymectomy for patients without thymoma below age 60 years who have generalized MG and either have AChR antibodies, or have no detectable AChR or MuSK antibodies (ie, seronegative MG) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest",
"      <strong>",
"       not",
"      </strong>",
"      performing thymectomy in patients with MuSK antibody-associated MG without thymoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Generalized myasthenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Age 60 and over'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link\">",
"       \"Thymectomy for myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attempted surgical excision is the treatment of choice for nonmetastatic thymoma and thymic carcinoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=see_link&amp;anchor=H1626413#H1626413\">",
"       \"Clinical presentation and management of thymoma and thymic carcinoma\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of drugs can unmask or exacerbate MG (",
"      <a class=\"graphic graphic_table graphicRef62302 \" href=\"UTD.htm?11/61/12254\">",
"       table 2",
"      </a>",
"      ). Avoidance of aminoglycoside antibiotics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      , and interferon-alpha in patients with MG is prudent. Likewise, beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      should be avoided when possible. Cautious use of drugs listed in the table (",
"      <a class=\"graphic graphic_table graphicRef62302 \" href=\"UTD.htm?11/61/12254\">",
"       table 2",
"      </a>",
"      ), particularly the neuromuscular blocking agents, is advised whenever there is a clear requirement for any of these agents. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Drugs that may exacerbate myasthenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of MG is highly individualized and depends upon the age of the patient, the severity of the disease, and the pace of progression. Treatment options and suggestions for generalized MG, ocular MG, patients over 60, and children are discussed in detail above. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Generalized myasthenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Ocular myasthenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Age 60 and over'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all individuals with generalized MG, and those with ocular MG who are within three years of onset, we suggest pneumococcal vaccination and annual intramuscular (inactivated) seasonal influenza vaccination (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients being treated with immunotherapy for MG should",
"      <strong>",
"       not",
"      </strong>",
"      receive the live-attenuated (intranasal) influenza vaccine. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Immunizations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of MG in pregnancy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36567?source=see_link\">",
"       \"Management of myasthenia gravis in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of rapidly worsening MG and myasthenic crisis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"       \"Myasthenic crisis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/1\">",
"      Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/2\">",
"      Farrugia ME, Vincent A. Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 2010; 23:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/3\">",
"      Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003; 61:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/4\">",
"      Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004; 29:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/5\">",
"      Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/6\">",
"      Punga AR, St&aring;lberg E. Acetylcholinesterase inhibitors in MG: to be or not to be? Muscle Nerve 2009; 39:724.",
"     </a>",
"    </li>",
"    <li>",
"     Liu GT, Volpe NJ, Galetta SL. Eyelid and facial nerve disorders. In: Neuro-Ophthalmology, Liu GT, Volpe NJ, Galetta SL.  (Eds), WB Saunders, Philadelphia 2001. p.496.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/8\">",
"      Ionita CM, Acsadi G. Management of juvenile myasthenia gravis. Pediatr Neurol 2013; 48:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/9\">",
"      Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve 2009; 39:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/10\">",
"      Dau PC, Lindstrom JM, Cassel CK, et al. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977; 297:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/11\">",
"      Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 1978; 28:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/12\">",
"      Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002; :CD002275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/13\">",
"      Benny WB, Sutton DM, Oger J, et al. Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients. Transfusion 1999; 39:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/14\">",
"      Miyahara T, Oka K, Nakaji S. Specific immunoadsorbent for myasthenia gravis treatment: development of synthetic peptide designed to remove antiacetylcholine receptor antibody. Ther Apher 1998; 2:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/15\">",
"      Nakaji S, Hayashi N. Adsorption column for myasthenia gravis treatment: Medisorba MG-50. Ther Apher Dial 2003; 7:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/16\">",
"      Rodnitzky RL, Goeken JA. Complications of plasma exchange in neurological patients. Arch Neurol 1982; 39:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/17\">",
"      P&eacute;rez Nellar J, Dom&iacute;nguez AM, Llorens-Figueroa JA, et al. [A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia]. Rev Neurol 2001; 33:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/18\">",
"      Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol 2005; 252 Suppl 1:I14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/19\">",
"      Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2012; 12:CD002277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/20\">",
"      Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/21\">",
"      Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007; 68:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/22\">",
"      Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011; 76:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/23\">",
"      Arsura E. Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 1989; 53:S170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/24\">",
"      Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 1991; 84:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/25\">",
"      Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999; 22:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/26\">",
"      Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004; 102:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/27\">",
"      Tsuchida M, Yamato Y, Souma T, et al. Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg 1999; 67:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/28\">",
"      Evoli A, Batocchi AP, Minisci C, et al. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 2000; 48:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/29\">",
"      Andrews PI. Autoimmune myasthenia gravis in childhood. Semin Neurol 2004; 24:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/30\">",
"      Tracy MM, McRae W, Millichap JG. Graded response to thymectomy in children with myasthenia gravis. J Child Neurol 2009; 24:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/31\">",
"      Evoli A. Acquired myasthenia gravis in childhood. Curr Opin Neurol 2010; 23:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/32\">",
"      Kolski H, Vajsar J, Kim PC. Thoracoscopic thymectomy in juvenile myasthenia gravis. J Pediatr Surg 2000; 35:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/33\">",
"      Andrews PI, Massey JM, Howard JF Jr, Sanders DB. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology 1994; 44:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/34\">",
"      Wittbrodt ET. Drugs and myasthenia gravis. An update. Arch Intern Med 1997; 157:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/35\">",
"      Barrons RW. Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy 1997; 17:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/36\">",
"      Russell AS, Lindstrom JM. Penicillamine-induced myasthenia gravis associated with antibodies to acetylcholine receptor. Neurology 1978; 28:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/37\">",
"      Kuncl RW, Pestronk A, Drachman DB, Rechthand E. The pathophysiology of penicillamine-induced myasthenia gravis. Ann Neurol 1986; 20:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/38\">",
"      Nieman RB, Sharma K, Edelberg H, Caffe SE. Telithromycin and myasthenia gravis. Clin Infect Dis 2003; 37:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/39\">",
"      Perrot X, Bernard N, Vial C, et al. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 2006; 67:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/40\">",
"      Dillon FX. Anesthesia issues in the perioperative management of myasthenia gravis. Semin Neurol 2004; 24:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/41\">",
"      Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet 2002; 360:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/42\">",
"      Engel WK. Reversible ocular myasthenia gravis or mitochondrial myopathy from statins? Lancet 2003; 361:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/43\">",
"      Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology 2004; 63:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/44\">",
"      Purvin V, Kawasaki A, Smith KH, Kesler A. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Medicine (Baltimore) 2006; 85:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/45\">",
"      Oh SJ, Dhall R, Young A, et al. Statins may aggravate myasthenia gravis. Muscle Nerve 2008; 38:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/46\">",
"      Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997; 48:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/57/7066/abstract/47\">",
"      Zinman L, Thoma J, Kwong JC, et al. Safety of influenza vaccination in patients with myasthenia gravis: a population-based study. Muscle Nerve 2009; 40:947.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5157 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7066=[""].join("\n");
var outline_f6_57_7066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYMPTOMATIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pyridostigmine dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Alleviating side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cholinergic crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHRONIC IMMUNOTHERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RAPID IMMUNOTHERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Course of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dose and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      THERAPEUTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Generalized myasthenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Addition of immunomodulating agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Bridge therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60761455\">",
"      - Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Need for thymectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ocular myasthenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Age 60 and over",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pregnancy and the neonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Myasthenic crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Drugs that may exacerbate myasthenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5157\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5157|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/56/5004\" title=\"table 1\">",
"      Therapies for MG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/61/12254\" title=\"table 2\">",
"      Drugs that may worsen MG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=related_link\">",
"      Chronic immunomodulating therapies for myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=related_link\">",
"      Clinical presentation and management of thymoma and thymic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=related_link\">",
"      Complications of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15654?source=related_link\">",
"      Differential diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36567?source=related_link\">",
"      Management of myasthenia gravis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=related_link\">",
"      Myasthenic crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=related_link\">",
"      Ocular myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/14/14562?source=related_link\">",
"      Patient information: Myasthenia gravis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=related_link\">",
"      Thymectomy for myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_57_7067="Cocaine kinetics";
var content_f6_57_7067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cocaine kinetics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Route of exposure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Peak action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous",
"       </td>",
"       <td>",
"        &lt;1 minute",
"       </td>",
"       <td>",
"        3-5 minutes",
"       </td>",
"       <td>",
"        30-60 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal",
"       </td>",
"       <td>",
"        1-5 minutes",
"       </td>",
"       <td>",
"        20-30 minutes",
"       </td>",
"       <td>",
"        60-120 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoking",
"       </td>",
"       <td>",
"        &lt;1 minute",
"       </td>",
"       <td>",
"        3-5 minutes",
"       </td>",
"       <td>",
"        30-60 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        30-60 minutes",
"       </td>",
"       <td>",
"        60-90 minutes",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7067=[""].join("\n");
var outline_f6_57_7067=null;
var title_f6_57_7068="Likelihood of pregnancy by findings on history and physical exam";
var content_f6_57_7068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of studies reporting likelihood ratios for prediction of pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        History",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive likelihood ratio (95% confidence interval)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Delayed menses",
"       </td>",
"       <td>",
"        2.06 (95% CI 1.65-2.57)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.04 (95% CI 0.38-2.87)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.13 (95% CI 1.05-2.92)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.56 (95% CI 1.4-1.74)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        No birth control",
"       </td>",
"       <td>",
"        1.31 (95% CI 1.14-1.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.53 (95% CI 1.06-2.18)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Patient suspects that she is pregnant",
"       </td>",
"       <td>",
"        1.6 (95% CI 1.39-1.85)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.15 (95% CI 2.37-4.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.6 (95% CI 1.39-1.85)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.11 (95% CI 1.97-2.27)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morning sickness",
"       </td>",
"       <td>",
"        2.7 (95% CI 2.19-3.33)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any pregnancy symptoms (defined as morning sickness, breast tenderness and fullness, urinary frequency, or fatigue)",
"       </td>",
"       <td>",
"        2.43 (95% CI 1.71-3.44)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Characteristic breast changes on physical examination",
"       </td>",
"       <td>",
"        2.71 (95% CI 2.3-3.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palpable fundus on physical examination",
"       </td>",
"       <td>",
"        2.77 (95% CI 1.7-4.51).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chadwick sign present",
"       </td>",
"       <td>",
"        3.17 (95% CI 2.22-4.51)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine artery pulsations present",
"       </td>",
"       <td>",
"        10.98 (95% CI 5.63-21.4)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7068=[""].join("\n");
var outline_f6_57_7068=null;
var title_f6_57_7069="Estimating body fat";
var content_f6_57_7069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methods of estimating body fat and its distribution",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cost",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ease of Use",
"       </td>",
"       <td class=\"subtitle1\">",
"        Accuracy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Measures Regional Fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Height and weight",
"       </td>",
"       <td>",
"        $",
"       </td>",
"       <td>",
"        Easy",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin folds",
"       </td>",
"       <td>",
"        $",
"       </td>",
"       <td>",
"        Easy",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Circumferences",
"       </td>",
"       <td>",
"        $",
"       </td>",
"       <td>",
"        Easy",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultrasound",
"       </td>",
"       <td>",
"        $$",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\" rowspan=\"1\">",
"        Density",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immersion",
"       </td>",
"       <td class=\"sublist_other\">",
"        $",
"       </td>",
"       <td class=\"sublist_other\">",
"        Moderate",
"       </td>",
"       <td class=\"sublist_other\">",
"        High",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Plethysmograph",
"       </td>",
"       <td class=\"sublist_other\">",
"        $$$",
"       </td>",
"       <td class=\"sublist_other\">",
"        Difficult",
"       </td>",
"       <td class=\"sublist_other\">",
"        High",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\" rowspan=\"1\">",
"        Heavy water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tritiated*",
"       </td>",
"       <td class=\"sublist_other\">",
"        $$",
"       </td>",
"       <td class=\"sublist_other\">",
"        Moderate",
"       </td>",
"       <td class=\"sublist_other\">",
"        High",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Deuterium oxide or heavy oxygen",
"       </td>",
"       <td class=\"sublist_other\">",
"        $$$",
"       </td>",
"       <td class=\"sublist_other\">",
"        Moderate",
"       </td>",
"       <td class=\"sublist_other\">",
"        High",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium isotope (40K)",
"       </td>",
"       <td>",
"        $$$$",
"       </td>",
"       <td>",
"        Difficult",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total body electrical conductivity",
"       </td>",
"       <td>",
"        $$$",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bioelectric impedance (BIA)",
"       </td>",
"       <td>",
"        $$",
"       </td>",
"       <td>",
"        Easy",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absorptiometry (dual energy X-ray = DEXA; dual photon = DPA)",
"       </td>",
"       <td>",
"        $$$",
"       </td>",
"       <td>",
"        Easy",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Computed tomography*",
"       </td>",
"       <td>",
"        $$$$",
"       </td>",
"       <td>",
"        Difficult",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnetic resonance imaging",
"       </td>",
"       <td>",
"        $$$$",
"       </td>",
"       <td>",
"        Difficult",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Radiation involved.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7069=[""].join("\n");
var outline_f6_57_7069=null;
var title_f6_57_7070="Paclitaxel and carboplatin chemotherapy for EOC";
var content_f6_57_7070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Paclitaxel and carboplatin chemotherapy for advanced epithelial ovarian cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        <p>",
"         Cycle length: 21 days.",
"        </p>",
"        Total cycles: 6 (in first-line setting).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Paclitaxel",
"        </strong>",
"       </td>",
"       <td>",
"        175 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 1000 mL normal saline (NS) or 5 percent dextrose in water (D5W) and administer over three hours*.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Carboplatin",
"        </strong>",
"       </td>",
"       <td>",
"        AUC",
"        <sup>",
"         &Delta;",
"        </sup>",
"        = 6",
"        <sup>",
"         &loz;",
"        </sup>",
"        mg/mL x min IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS or D5W and administer over 30 minutes (administer after the completion of the paclitaxel infusion).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE (30 to 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Paclitaxel may cause severe hypersensitivity reactions. Premedication regimen should include dexamethasone (either 20 mg orally twelve and six hours before, or 20 mg IV 30 minutes before drug administration) plus both an H1 (diphenhydramine 25 to 50 mg IV) and an H2 receptor antagonist (ranitidine 50 mg or famotidine 20 mg IV) 30 to 60 minutes prior to paclitaxel administration",
"        <sup>",
"         [2]",
"        </sup>",
"        . Severe infusion reactions (eg, skin rash, flushing, dyspnea, urticaria, back pain, hypotension, chest pain, tachycardia) occur primarily during the first and second infusions, typically within the first hour after the start of the infusion. Further information on infusion reactions, including management, is available. Carboplatin is also associated with infusion reactions. However, they usually occur after six cycles, and no specific premedication regimen is recommended. Further information on infusion reactions, including skin testing and desensitization, is available. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Paclitaxel can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Not applicable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Serum electrolytes and liver and renal function tests prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity toxicity:",
"        </strong>",
"        Treatment with paclitaxel and carboplatin should be delayed until the absolute neutrophil count is greater than 1500/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is greater than 100,000/mm",
"        <sup>",
"         3[2,3]",
"        </sup>",
"        . If a patient developed severe neutropenia (&lt;500/mm",
"        <sup>",
"         3",
"        </sup>",
"        ) for a week or longer, or febrile neutropenia during the prior course, then the paclitaxel and carboplatin doses should be reduced by 20 to 25 percent for subsequent courses or initiation of hematopoietic growth factor support. Both the carboplatin and paclitaxel doses should be decreased by 25 percent in patients whose platelet count nadir is &lt;25,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        for longer than five days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        For patients who develop severe neuropathy (grade 3 or 4) for a week or longer, then the dose of paclitaxel should be reduced by 20 percent for subsequent courses",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for liver or renal dysfunction:",
"        </strong>",
"        Alterations in renal function during therapy may require a recalculation of the carboplatin dose. Paclitaxel dose may need to be adjusted for hepatic impairment on day 1 of each cycle. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose recalculation for both drugs should be considered.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; GFR: glomerular filtration rate.",
"     <br>",
"      * Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.",
"      <br>",
"       &Delta; AUC (area under the concentration X time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) x (GFR + 25). If an estimated GFR based upon measured serum creatinine is used in the Calvert equation, and renal function is normal, clinicians should consider capping the GFR at 125 mL/min, at least for the first dose. This recommendation does not apply if the GFR is directly measured. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on Carboplatin.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Many clinicians use a slightly higher carboplatin dose (AUC 7.5 mg/mL x min) for patients with a good performance status.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Bolis G, et al. J Clin Oncol 2004; 22:686.",
"      </li>",
"      <li>",
"       Taxol (paclitaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 8, 2011).",
"      </li>",
"      <li>",
"       Carboplatin injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 8, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_57_7070=[""].join("\n");
var outline_f6_57_7070=null;
var title_f6_57_7071="Contents: Asthma";
var content_f6_57_7071=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/1/44061\">",
"       Allergy and Immunology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Asthma",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Asthma",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Asthma triggers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39944\">",
"           Aspirin exacerbated respiratory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1513\">",
"           Exercise-induced bronchoconstriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/42/34472\">",
"           Nocturnal asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/44/22216\">",
"           Treatment of recurrent virus-induced wheezing in young children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/15/2298\">",
"           Virus-induced wheezing and asthma: An overview",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Epidemiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/12/19653\">",
"           Epidemiology of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/29/10713\">",
"           Genetics of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/13/7383\">",
"           Natural history of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/12/20682\">",
"           Risk factors for asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/27/36278\">",
"           Severe asthma: Evidence for heterogeneity of the disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/4/1098\">",
"           Bronchoprovocation testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/43/5818\">",
"           Diagnosis and management of asthma in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/1/19482\">",
"           Diagnosis of asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/48/36613\">",
"           Diagnosis of wheezing illnesses other than asthma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/40/32391\">",
"           Evaluation of pulmonary disability",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/49/14105\">",
"           Evaluation of severe asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/18/5418\">",
"           Evaluation of subacute and chronic cough in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/15/7416\">",
"           Exhaled nitric oxide analysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25878\">",
"           Flow-volume loops",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/26/13735\">",
"           Identifying patients at risk for fatal asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/15/36089\">",
"           Occupational asthma: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/30/5607\">",
"           Office spirometry",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/53/4952\">",
"           Overview of pulmonary function testing in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/53/854\">",
"           Peak expiratory flow rate monitoring in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/61/22487\">",
"           Use of pulmonary function testing in the diagnosis of asthma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Occupational asthma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/15/36089\">",
"           Occupational asthma: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/0/34824\">",
"           Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/9/14489\">",
"           Occupational asthma: Management, prognosis, and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/63/38903\">",
"           Occupational asthma: Pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/28/8650\">",
"           Reactive airways dysfunction syndrome and irritant-induced asthma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/56/39816\">",
"           Gastroesophageal reflux and asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17177\">",
"           Nonselective NSAIDs: Overview of adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/11/16567\">",
"           Paradoxical vocal cord motion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/45/19159\">",
"           Physiology and clinical course of asthma in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/53/27482\">",
"           Smoking and pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/48/33545\">",
"           Allergic bronchopulmonary aspergillosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/56/15239\">",
"           Beta-2 adrenergic receptor dysfunction and polymorphism in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/29/10713\">",
"           Genetics of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/60/10186\">",
"           Neuronal control of the airways",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/63/38903\">",
"           Occupational asthma: Pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/52/4937\">",
"           Pathogenesis of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/27/36278\">",
"           Severe asthma: Evidence for heterogeneity of the disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30746\">",
"           Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/48/34569\">",
"           Allergen avoidance in the treatment of asthma and allergic rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/36/33354\">",
"           Alternative and experimental agents for the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/37/8794\">",
"           An overview of asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/46/17130\">",
"           Anti-IgE therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/24/20870\">",
"           Anticholinergic agents in the management of acute exacerbations of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/26/8618\">",
"           Beta agonists in asthma: Acute administration and prophylactic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/19/16698\">",
"           Beta agonists in asthma: Controversy regarding chronic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/20/18762\">",
"           Delivery of inhaled medication in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/61/31703\">",
"           Determinants of glucocorticoid dosing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/31/12789\">",
"           Enhancing patient adherence to asthma therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/37/22103\">",
"           Glucocorticoid withdrawal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/42/7849\">",
"           Glucocorticoid-resistant asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/18/10535\">",
"           Invasive mechanical ventilation in adults with acute exacerbations of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/60/7114\">",
"           Major side effects of inhaled glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/47/27386\">",
"           Major side effects of systemic glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/34/29226\">",
"           Management of asthma during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/51/22325\">",
"           Molecular effects of inhaled glucocorticoid therapy in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/54/42855\">",
"           Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/54/30568\">",
"           Physiology and clinical use of heliox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/36/17994\">",
"           Prevention and treatment of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/29/471\">",
"           The use of chromones (cromoglycates) in the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/26/18856\">",
"           The use of inhaler devices in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/16/13578\">",
"           Theophylline poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11161\">",
"           Theophylline use in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/56/5002\">",
"           Treatment of acute exacerbations of asthma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/62/2021\">",
"           Treatment of hypertension in asthma and COPD",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18154\">",
"           Treatment of intermittent and mild persistent asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/7/26745\">",
"           Treatment of moderate persistent asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/17/3354\">",
"           Treatment of severe asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/16/27913\">",
"           Treatment of subacute and chronic cough in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/9/44184\">",
"           Trigger control to enhance asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/15/31991\">",
"           What do patients need to know about their asthma?",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-4EB0964EE1-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_57_7071=[""].join("\n");
var outline_f6_57_7071=null;
